Biotechnology and Biopharma News

A more refined equine transcriptome
Transcriptome interpretation relies on a good-quality reference transcriptome for accurate quantification of gene expression as well as functional analysis of genetic variants. The current annotation of the horse genome lacks the specificity and sensitivity necessary to assess gene expression especially at the isoform level, and suffers from insufficient annotation of untranslated regions (UTR) usage. Researchers ...
01/23/17, Transcriptome Research & Industry News

Study investigates use of glucose to shorten induced labor in nulliparous woman
In a study to be presented Thursday, Jan. 26, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers with the Université de Sherbrooke in Sherbrooke, Quebec, Canada will present their findings in a study titled, Reduction of total labor length through the addition of parenteral dextrose solution in induction of labor in nulliparous: results of DEXTRONS prospective randomized controlled trial.
01/23/17, News Medical Life Sciences

Study compares suture types for skin closure in cesarean delivery
In a study to be presented Thursday, Jan. 26, in the oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting,
01/23/17, News Medical Life Sciences

Sapientia genome analysis software by Congenica could cut costs and save lives
Whole genome analysis (WGA) enables rapid diagnosis of rare disease, ensuring that an appropriate course of management and treatment can be administered, possibly within days for acute neonatal cases, cutting the cost of intensive care and potentially saving lives. Rapid diagnosis is one of the many benefits of using the Sapientia™ genome analysis and interpretation platform that Dr Nick Lench, Chief Operating Officer of Congenica, will be discussing at Precision Medicine World Conference (PMWC) 2017 on January 23rd at 3.15pm.
01/23/17, News Medical Life Sciences

Researchers evaluate effects of laser tissue welding on spina bifida repair
In a study to be presented Saturday, Jan. 28, in the oral concurrent session at 8:45 a.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, researchers at Baylor College of Medicine, Houston, Texas; IBEX, Logan, Utah; and Laser Tissue Welding Inc., Houston, Texas collaborated on a study titled, Evaluation of the effects of laser tissue welding on the spinal cord and skin in a 30 day study of simulated spina bifida repair in rabbits.
01/23/17, News Medical Life Sciences

New whitepaper on temperature-related problems in drug delivery and storage, from Berlinger
‘Last mile’ transportation and subsequent user storage conditions present unique challenges when it comes to ensuring the safe and effective use of pharmaceutical products. Berlinger & Co. AG, a market leader in pharmaceutical temperature monitoring, has released a White Paper entitled “Beyond the Cold Chain” that discusses the temperature-related problems associated with the delivery and storage of drugs after they leave the primary supply chain.
01/23/17, News Medical Life Sciences

New biomarker helps better predict survival after surgical removal of colorectal metastases
Liver metastases are formed from cancer cells that have originated in other organs and migrated to the liver via the bloodstream. Colorectal cancer (cancer of the colon/rectum) can be successfully treated by surgical resection of the metastases in combination with chemotherapy.
01/23/17, News Medical Life Sciences

New AAV biosensor products announced by AMSBIO
AMSBIO announce a new range of ready-to-use adeno-associated virus (AAV) biosensor products. These viruses encode your chosen biosensor, either calcium or glutamate sensor and are ready for in vivo injection.
01/23/17, News Medical Life Sciences

E-cigarettes attracting youth to use tobacco products, new UC San Francisco study finds
E-cigarettes - thought by some to be responsible for a decline in youth cigarette smoking - are actually attracting a new population of adolescents who might not otherwise have smoked tobacco products, according to a new UC San Francisco study.
01/23/17, News Medical Life Sciences

Cervical cancer death rate among older and black women higher than previously thought
A woman's risk of dying of cervical cancer is higher than long believed, particularly among older and black women, new Johns Hopkins Bloomberg School of Public Health-led research suggests.
01/23/17, News Medical Life Sciences

A test to evaluate Hepatitis B therapy launched by Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.2 million individuals infected with HBV.
01/23/17, News Medical Life Sciences

mTORC1 phosphorylates LARP6 to stimulate type I collagen expression

01/23/17, Nature

Multi-omics analyses reveal metabolic alterations regulated by hepatitis B virus core protein in hepatocellular carcinoma cells

01/23/17, Nature

Hormetic effect of panaxatriol saponins confers neuroprotection in PC12 cells and zebrafish through PI3K/AKT/mTOR and AMPK/SIRT1/FOXO3 pathways

01/23/17, Nature

Enhancement of RecA-mediated self-assembly in DNA nanostructures through basepair mismatches and single-strand nicks

01/23/17, Nature

The kinetochore-dependent and -independent formation of the CDC20-MAD2 complex and its functions in HeLa cells

01/23/17, Nature

Insight into the essential role of the Helicobacter pylori HP1043 orphan response regulator: genome-wide identification and characterization of the DNA-binding sites

01/23/17, Nature

Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca2+-ATPase 2a

01/23/17, Nature

Erratum: Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy

01/23/17, Nature

Metagenomics: Mining for CRISPR–Cas

01/23/17, Nature

Diversity and evolution of class 2 CRISPR–Cas systems

01/23/17, Nature

Metagenomics: Uncultivated microbes reveal new CRISPR–Cas systems

01/23/17, Nature

Divergent prion strain evolution driven by PrPC expression level in transgenic mice

01/23/17, Nature

mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation

01/23/17, Nature

BMS and Ono Agree $625M Keytruda Patent Litigation Settlement with Merck
Merck & Co will have to pay Bristol-Myers Squibb and Ono Pharmaceutical an initial $625 million as part settlement of patent litigation against Merck’s programmed death-1 (PD-1) anticancer antibody, Keytruda® (pembrolizumab).  Bristol-Myers Squibb and Ono claimed that Keytruda sales infringed on their own PD-1 antibody patents, which underpin Bristol-Myers Squibb’s antibody therapeutic, Opdivo (nivolumab). The settlement, reported late Friday, also requires Merck to pay 6.5% royalties on global sales of Keytruda through to the end of 2023, and then 2.5% royalties until the end of 2026. The royalties will be split 75/25 between Bristol-Myers Squibb and Ono, respectively. The agreement allows for the companies to give each other specific rights under their respective PD-1 patent portfolios.  Commenting on the settlement, Bristol-Myers Squibb CEO, Giovanni Caforio, M.D. said, “Bristol-Myers Squibb and Ono’s agreement with Merck protects our scientific discoveries and validates the strong intellectual property rights we secured ...
01/23/17, Genetic Engineering & Biotech News

New genetic engineering technique could help design, study biological systems
A new technique will help biologists tinker with genes, whether the goal is to turn cells into tiny factories churning out medicines, modify crops to grow with limited water or study the effects of a gene on human health. The technique allows scientists to precisely regulate how much protein is produced from a particular gene. The process is simple yet innovative and, so far, works in everything from bacteria to plants to human cells.
01/20/17, ScienceDaily

Lipids Take the Lead in Metastasis
Researchers find diverse ways that the molecules can regulate cancer’s spread.
01/20/17, The Scientist

Genome Digest
What researchers are learning as they sequence, map, and decode species’ genomes
01/20/17, The Scientist

RNA-Seq uncovers cellular responses to bird flu vaccine
New research from Vanderbilt eavesdrops on gene expression in human immune system cells before and after vaccination against bird flu. Reported in the journal PLOS One, the study exposes cellular responses associated with a vaccine constituent called AS03, short for adjuvant system 03. Using massive computation, the investigators pursue a systems biology approach, providing a ...
01/20/17, Transcriptome Research & Industry News

Feasibility of sample size calculation for RNA-seq studies
Sample size calculation is a crucial step in study design but is not yet fully established for RNA sequencing (RNA-seq) analyses. To evaluate feasibility and provide guidance, researchers from the Johannes Gutenberg University Mainz evaluated RNA-seq sample size tools identified from a systematic search. The focus was on whether real pilot data would be needed ...
01/20/17, Transcriptome Research & Industry News

Shire refiles ADHD drug
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.
01/20/17, PharmaTimes

Imbruvica gets US nod for marginal zone lymphoma
Janssen and AbbVie's Imbruvica has been cleared by regulators in the US to treat certain patients with marginal zone lymphoma (MZL), a rare form of non-Hodgkin's lymphoma.
01/20/17, PharmaTimes

GSK poaches AZ’ Luke Miels for pharma business
GlaxoSmithKline has announced that AstraZeneca's Luke Miels has been appointed president of its Global Pharmaceuticals division.
01/20/17, PharmaTimes

ABPI slams new plans for drug appraisals
The Association of the British Pharmaceutical Industry has described new proposals for evaluating medicines for NHS use as "heavy handed" and "unrealistic".
01/20/17, PharmaTimes

Heterogeneous nuclear ribonucleoprotein M associates with mTORC2 and regulates muscle differentiation

01/20/17, Nature

SRRM4-dependent neuron-specific alternative splicing of protrudin transcripts regulates neurite outgrowth

01/20/17, Nature

Secreted miR-27a Induced by Cyclic Stretch Modulates the Proliferation of Endothelial Cells in Hypertension via GRK6

01/20/17, Nature

The systematic analysis of coding and long non-coding RNAs in the sub-chronic and chronic stages of spinal cord injury

01/20/17, Nature

Comparative Phosphoproteomics Reveals an Important Role of MKK2 in Banana (Musa spp.) Cold Signal Network

01/20/17, Nature

The β-globin Replicator greatly enhances the potential of S/MAR based episomal vectors for gene transfer into human haematopoietic progenitor cells

01/20/17, Nature

Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro

01/20/17, Nature

Werfen and IL Buy POC Diagnostics Firm Accriva
Spanish in vitro diagnostics (IVD) firm Werfen and its Bedford, MA-based subsidiary Instrument Laboratory (IL) have acquired Accriva, a point-of-care (POC) diagnostics company specialized in systems for coagulation testing and antiplatelet therapy response. The transaction, which closed yesterday, but for which details have not been disclosed, will see Accriva become part of IL and continue to operate out of its facilities in San Diego, CA, where some 460 staff are employed. IL is a global developer, manufacturer, and distributor of IVD instruments, reagents, and data management solutions for the hospital and clinical laboratory markets. The firm says the acquisition of Accriva will boost its position in POC critical care testing, allow it to establish a presence in hospital-based POC hemostasis testing, and bolster its existing capabilities in laboratory hemostasis testing. "The acquisition of Accriva strengthens our leadership in hemostasis, critical care, and patient blood management testing," said Ramon ...
01/20/17, Genetic Engineering & Biotech News

Trump Keeps Collins at NIH Helm, for the Moment
Francis S. Collins, M.D., Ph.D., will remain as NIH director on a temporary basis into the administration of Donald J. Trump, who will be sworn in today as the nation’s 45 th president. “We learned late yesterday that Dr. Francis Collins has been held over by the Trump administration,” NIH spokeswoman Renate Myles told GEN today. “We have no additional details at this time.” The NIH referred further questions to Trump’s transition team, which to date has not commented on who the new administration wants to see at the agency’s helm. Dr. Collins—who previously said he remained open to remaining in his position in the new administration—was one of two people who met with Trump earlier this month in what news reports said were conversations about leading NIH. The other person was Rep. Andy Harris, M.D. (R-MD), an obstetric anesthesiologist who was easily re-elected to ...
01/20/17, Genetic Engineering & Biotech News

Stalling Elongation a Fast Way to Slow Gene Expression
Full speed. Half speed. Full stop. Those are the usual choices for controlling the amount of protein produced from a particular gene. Other speeds are possible, but they typically require a lot of effort on the part of scientists, who often resort to the identification and exploitation of a hypomorphic mutation, that is, a mutation that causes a partial loss of gene function. Hypomorphic mutations, however, are usually hard to come by. They may be limited to a specific organism, change gene expression unpredictably, or depend on changes in the spatial–temporal expression of the targeted gene. Yet problems such as these may be avoided, report scientists based at the Washington University School of Medicine in St. Louis. These scientists assert that they have developed a simple and predictable method to generate hypomorphic mutations in model organisms by targeting translation elongation. The method appeared January 20 in the ...
01/20/17, Genetic Engineering & Biotech News

Ginkgo Bioworks Acquires Gen9
Ginkgo Bioworks said today it has acquired synthetic DNA provider Gen9 for an undisclosed price, in a deal the buyer said will enable it to improve its speed and capacity in constructing new organism designs for use across multiple industries. The acquisition, Ginkgo said, will bring Gen9's expertise in assembling pathway-length synthetic DNA into its automated organism-engineering foundries. Ginkgo's facilities will house Gen9's BioFab ® manufacturing platform and proprietary technologies, software, and informatics tools, as well as Gen9's intellectual property portfolio of more than 125 patents and patents pending related to DNA synthesis and assembly technologies. Gen9's operations and research and development teams will also join Ginkgo, bringing with them their expertise in gene synthesis. “Ginkgo has been our largest customer in recent years, and we're thrilled to join forces and together forge a new trajectory for bringing the benefits of synthetic DNA to ...
01/20/17, Genetic Engineering & Biotech News

FDA Approves Synergy's Constipation Drug Trulance
Synergy Pharmaceuticals confirmed that FDA has approved Trulance™ (plecanatide), a once-daily, oral drug for treating chronic idiopathic constipation (CIC) in adults. The guanylate cyclase-C (GC-C) agonist is designed to mimic the human gastrointestinal peptide uroguanylin. Launch of Trulance in the U.S. is expected during Q1 2017. Synergy says about 33 million people in the U.S. and 14% of the global population suffer with CIC, which doesn't have an identifiable cause. “We are thrilled with the approval of Trulance because it provides an additional, much-needed, new treatment option to help adults with chronic idiopathic constipation and their healthcare providers manage this condition,” said Gary S. Jacob, Ph.D., chairman and CEO of Synergy Pharmaceuticals. FDA approval of Trulance was based on data from two placebo-controlled Phase III studies, which enrolled more than 2600 patients. The trial data showed that Trulance-treated patients achieved a greater efficacy response rate and improvements ...
01/20/17, Genetic Engineering & Biotech News

Discovery of Bacteria's Immune System-Avoiding Strategy May Lead to New Therapies
Researchers have discovered how a unique bacterial enzyme can blunt the body's key weapons in its fight against infection. A team at the University of Illinois at Urbana–Champaign and Newcastle University in the U.K. are investigating how infectious microbes can survive attacks by the body's immune system. By better understanding the bacteria's defenses, new strategies can be developed to cure infections that are currently resistant to treatments, the researchers said. The study ("A Superoxide Dismutase Capable of Functioning with Iron or Manganese Promotes the Resistance of Staphylococcus aureus to Calprotectin and Nutritional Immunity”) reported in PLOS Pathogens , focused on the bacterium Staphylococcus aureus , which is found in approximately half of the population. While it usually safely co-exists with healthy individuals, S. aureus has the ability to infect nearly the entire body; in its most pathogenic form, the bacterium is the so-called "superbug" methicillin-resistant S. aureus , or MRSA.  ...
01/20/17, Genetic Engineering & Biotech News

Could This Be Why Alzheimer’s Patients Wander?
Its estimated that three out of five people with Alzheimer's disease (AD) wander and get lost, usually beginning in the early stages of the disease, leaving them vulnerable to injury. Researchers have suspected that along with memory deficiencies the disease also affects the navigational centers—or GPS—of the brain. Now, investigators from Columbia University Medical Center (CUMC) have recently discovered that the spatial disorientation that leads to wandering in many Alzheimer's disease patients is caused by the accumulation of tau protein in navigational nerve cells within the brain.    These new findings in mice, which were just published online in Neuron in an article entitled “Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction and Spatial Memory Deficits Reminiscent of Early Alzheimer’s Disease,” could lead to early diagnostic tests for Alzheimer's and highlight novel targets for treating this common and troubling symptom. The CUMC team hypothesized that AD ...
01/20/17, Genetic Engineering & Biotech News

Pharma joins Gates Foundation, international governments in $1B outbreak prep group
Pharma joins Gates Foundation, international governments in $1B outbreak prep group esagonowsky Fri, 01/20/2017 - 11:26
01/20/17, Fierce Pharma

Restless Sanofi investors want to see it get its M&A act together
Restless Sanofi investors want to see it get its M&A act together epalmer Fri, 01/20/2017 - 09:44
01/20/17, Fierce Pharma

Eli Lilly slashes 485 jobs, with ax falling heavily on faltering Alzheimer’s unit
Eli Lilly slashes 485 jobs, with ax falling heavily on faltering Alzheimer’s unit arlene.weintraub Fri, 01/20/2017 - 09:46
01/20/17, Fierce Pharma

Government still has 'no settlement' with Mylan, CMS administrator says
Government still has 'no settlement' with Mylan, CMS administrator says esagonowsky Fri, 01/20/2017 - 09:50
01/20/17, Fierce Pharma

Another Opdivo setback for Bristol, this time on the combo front, widening Merck's immuno-oncology lead
Another Opdivo setback for Bristol, this time on the combo front, widening Merck's immuno-oncology lead chelfand Fri, 01/20/2017 - 10:33
01/20/17, Fierce Pharma

FiercePharmaAsia: Astellas' failed vax collab, Takeda's rare disease pact, Sanpower's Dendreon facilities
FiercePharmaAsia: Astellas' failed vax collab, Takeda's rare disease pact, Sanpower's Dendreon facilities aliu Fri, 01/20/2017 - 08:28
01/20/17, Fierce Pharma

Synergy's Trulance wins an OK to battle Allergan's Linzess in CIC—and IBS-C could be next
Synergy's Trulance wins an OK to battle Allergan's Linzess in CIC—and IBS-C could be next chelfand Fri, 01/20/2017 - 11:09
01/20/17, Fierce Pharma

Novel ‘FishTaco’ computational method links gut microbes with disease
Novel ‘FishTaco’ computational method links gut microbes with disease arlene.weintraub Fri, 01/20/2017 - 12:00
01/20/17, Fierce Biotech

Philadelphia consortium funds three companies developing pediatric devices
Philadelphia consortium funds three companies developing pediatric devices aalidrus Fri, 01/20/2017 - 10:36
01/20/17, Fierce Biotech

OssDsign gets FDA clearance for 3D-printed cranial implant
OssDsign gets FDA clearance for 3D-printed cranial implant nick.paul.taylor Fri, 01/20/2017 - 09:41
01/20/17, Fierce Biotech

FDA issues draft guidances on drug, device labeling
FDA issues draft guidances on drug, device labeling aalidrus Fri, 01/20/2017 - 09:04
01/20/17, Fierce Biotech

After Cinven deal, Bioclinica starts hiring spree in imaging, biomarkers
After Cinven deal, Bioclinica starts hiring spree in imaging, biomarkers badams Fri, 01/20/2017 - 04:31
01/20/17, Fierce Biotech

Pfizer joins Big Pharma peers in R&D matchmaking program
Pfizer joins Big Pharma peers in R&D matchmaking program nick.paul.taylor Fri, 01/20/2017 - 04:01
01/20/17, Fierce Biotech

Donald Trump’s first 100 days, and beyond, for biopharma
Donald Trump’s first 100 days, and beyond, for biopharma badams Fri, 01/20/2017 - 04:13
01/20/17, Fierce Biotech

Cytori to add cancer drugs, nanoparticle tech in Azaya deal
Cytori to add cancer drugs, nanoparticle tech in Azaya deal nick.paul.taylor Fri, 01/20/2017 - 05:24
01/20/17, Fierce Biotech

Catabasis lifted by early-stage muscular dystrophy data, but bigger test is coming soon
Catabasis lifted by early-stage muscular dystrophy data, but bigger test is coming soon phil Fri, 01/20/2017 - 07:58
01/20/17, Fierce Biotech

Two Pore Guys and UCSF Collaborate on Liquid Biopsy Study With First Handheld Device for Cancer Monitoring
Two Pore Guys, Inc., (2PG) today announced the company is collaborating with oncologists at the University of California, San Francisco (UCSF), to evaluate its handheld nanopore-based platform in the detection of cell-free, circulating tumor DNA (ctDNA) from patient liquid biopsies. The study, conducted by Andrew Ko, MD, will focus on detecting the KRAS G12D mutation ...
01/20/17, Exosome RNA Research & Industry News

Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression
Extracellular vesicles, including exosomes, constitute an important element of intercellular communication by carrying a variety of molecules from producer to target cells. The transport of mRNA and miRNA can directly modulate gene expression in the target cells. The miRNA content in exosomes is characteristic for the cell from which the vesicles were derived enabling the ...
01/20/17, Exosome RNA Research & Industry News

Toward a Virus-Free Polio Vaccine
Researchers are developing polio vaccines based on the viral capsid alone. When produced in recombinant systems, these could eliminate the need to propagate live poliovirus for vaccine production. 
01/19/17, The Scientist

Unknown Protein Structures Predicted
Metagenomic sequence data boosts the power of protein modeling software to yield hundreds of new protein structure predictions.
01/19/17, The Scientist

University of Lausanne researchers identify a novel natural killer-like cell type with single-cell RNA-Seq
The immune system of vertebrate species consists of many different cell types that have distinct functional roles and are subject to different evolutionary pressures. Here, University of Lausanne and Sanger Institute researchers first analysed conservation of genes specific for all major immune cell types in human and mouse. Their results revealed higher gene turnover and ...
01/19/17, Transcriptome Research & Industry News

hppRNA – a Snakemake-based handy parameter-free pipeline for RNA-Seq analysis of numerous samples
RNA-Seq technology has been gradually becoming a routine approach for characterizing the properties of transcriptome in terms of organisms, cell types and conditions and consequently a big burden has been put on the facet of data analysis, which calls for an easy-to-learn workflow to cope with the increased demands from a large number of laboratories ...
01/19/17, Transcriptome Research & Industry News

Choice of workflow leads to wide variation in gene expression results
RNA-Seq has supplanted microarrays as the preferred method of transcriptome-wide identification of differentially expressed genes. However, RNA-Seq analysis is still rapidly evolving, with a large number of tools available for each of the three major processing steps: read alignment, expression modeling, and identification of differentially expressed genes. Although some studies have benchmarked these tools against ...
01/19/17, Transcriptome Research & Industry News

UCB, Dermira plan psoriasis filing for Cimzia in Q3
UCB and Dermira are expecting to file anti-inflammatory Cimzia for psoriasis in the third quarter of this year, after the drug's strong performance in a late-stage trial involving patients with severe chronic plaque forms of the skin disease.
01/19/17, PharmaTimes

Lilly shells out $960m on CoLucid
Eli Lilly is buying US biopharma CoLucid in a deal worth around $960 million, in a move designed to boost its migraine pain management portfolio with a late-stage candidate offering a potential near-term market launch.
01/19/17, PharmaTimes

Last chance to enter International Clinical Researcher of the Year 2017
The PharmaTimes International Clinical Researcher of the Year 2017 offers unique career development opportunity for clinical researchers worldwide. The deadline for entry essays is Tuesday 31 January, so don't delay, enter today!
01/19/17, PharmaTimes

Clinical researchers in the Americas – connect with top researchers and showcase your talents and skills
Clinical researchers in the Americas: you've got until February 8 to take part in a prestigious competition that offers a unique career development opportunity. PharmaTimes Clinical Researcher of the Year – The Americas is open for entries!
01/19/17, PharmaTimes

Boehringer files Humira biosimilar in EU, US
Boehringer Ingeheim's biosimilar to AbbVie's mega blockbuster Humira has been accepted for review on both sides of the Atlantic, after having shown comparability in late-stage trials.
01/19/17, PharmaTimes

Coordinated cell motility is regulated by a combination of LKB1 farnesylation and kinase activity

01/19/17, Nature

Corrigendum: Pre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity

01/19/17, Nature

Viral microRNAs Target a Gene Network, Inhibit STAT Activation, and Suppress Interferon Responses

01/19/17, Nature

Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation

01/19/17, Nature

Corrigendum: Nanoimaging granule dynamics and subcellular structures in activated mast cells using soft X-ray tomography

01/19/17, Nature

Precise and efficient scarless genome editing in stem cells using CORRECT

01/19/17, Nature

α3 Chains of type V collagen regulate breast tumour growth via glypican-1

01/19/17, Nature

The impact of microRNAs on transcriptional heterogeneity and gene co-expression across single embryonic stem cells

01/19/17, Nature

RNA modification: Reading Sex-lethal

01/19/17, Nature

Basis of catalytic assembly of the mitotic checkpoint complex

01/19/17, Nature

Post-doc Position Available – Molecular Mechanisms of Gene Regulation
Position Title: Postdoctoral Research Associate_Calabrese Lab Vacancy ID: PDS001253 Department: Pharmacology – 424001 Position Type: Postdoctoral Scholar Full-time/Part-time: Full Time FTE: 1.0 Estimated Duration of Appointment: 12 Months Posting Open Date: 03/02/2016 Open Until Filled: Yes Work Location: Chapel Hill, NC Position Summary The Calabrese laboratory is seeking a postdoctoral fellow to study molecular mechanisms ...
01/19/17, lncRNA Research and Industry News

Extracellular vesicle associated long non-coding RNAs functionally enhance cell viability
Cells communicate with one another to create microenvironments and share resources. One avenue by which cells communicate is through the action of exosomes. Exosomes are extracellular vesicles that are released by one cell and taken up by neighbouring cells. But how exosomes instigate communication between cells has remained largely unknown. Researchers from the University of ...
01/19/17, lncRNA Research and Industry News

Telix Acquires Cancer Theranostics from Atlab and Therapeia, Plus Buyout Options
Telix Pharmaceuticals secured options to acquire Therapeia and Atlab Pharma as part of separate agreements to develop the two firms' radiolabeled anticancer candidates. The deals with Therapeia and Atlab follow just days after T elix acquired global rights to Wilex’s radiolabeled girentuximab candidate Redectane ® . Germany-based Therapeia’s lead product ACD-101 is a synthetic amino acid targeting the L-type amino acid transporter 1 (LAT1). The candidate is in clinical development as a radiolabeled diagnostic for positron emission tomography (PET) imaging and as a radiolabeled therapeutic candidate for the potential treatment of glioblastoma and other aggressive cancers. The firms say that more than 100 patients have been successfully imaged with ACD-101 to study biodistribution and kinetics, including patients with inoperable brain tumors. Clinical pilot studies for the therapeutic forms of ACD-101 have started in Europe. Telix has been established to develop and commercialize late-stage oncology assets, with a ...
01/19/17, Genetic Engineering & Biotech News

New Molecule Circumvents Antibiotic Resistance
Any assistance in the fight to thwart efforts of microbial pathogens to sidestep antibiotic drug mechanisms is a welcome addition to the arsenal researchers and physicians use to treat bacterial infections. Now, a team of investigators led by scientists at Oregon State University (OSU) has developed a new molecule that neutralizes a microbe’s ability to destroy antibiotic compounds. Beta-lactamases (also known as penicillinase) are a family of enzymes that are genetically encoded by many bacteria and destroy a wide range of antibiotic drugs, such as penicillins, cephamycins, and even some carbapenems, which are often the last line defense against certain microbial infections. This family of enzymes is responsible for conferring multidrug resistance in many bacterial species. The new molecule—named PPMO, short for peptide-conjugated phosphorodiamidate morpholino oligomer—was able to inhibit expression of a beta-lactamase molecule known as NDM-1, or New Delhi metallo-beta-lactamase .   "We're targeting a ...
01/19/17, Genetic Engineering & Biotech News

New Blood Test Can Predict Outcome for Ebola-Infected Patients
Scientists at the University of Liverpool, in collaboration with Public Health England, Boston University, and other international partners, say they used blood samples taken from infected and recovering patients during the 2013–2016 West Africa Ebola outbreak to identify gene products that act as strong predictors of patient outcome. The new research provides data on the underlying causes of Ebola virus infection and suggests that this type of blood analysis could be integrated into future outbreak responses as a diagnostic tool to help guide treatment strategies. Since the Ebola outbreak in West Africa, much research has been done to further understand the biology of the Ebola virus. In particular, the processes that lead to survival or a fatal infection are unknown, although the viral load can be a key determinant. However, while this premise worked well for predicting outcomes for people with extreme viral loads, it was less clear ...
01/19/17, Genetic Engineering & Biotech News

Evil Astrocytes Emit Neuron-Killing Toxin
Astrocytes are usually the good guys. Although they are four times as plentiful in the brain as neurons, they happily play a supporting role, serving as packing peanuts or facilitating the formation and pruning of neuronal connections. Yet good astrocytes, or resting astrocytes, can become what are known as reactive astrocytes, some of which turn evil, destroying nerve cells and likely driving many neurodegenerative diseases. The dark turn, which may be instigated by infection or trauma, has been detailed by scientists based at Stanford University Medical Center, who suggest that a broad range of brain disorders may be treatable by blocking astrocytes' metamorphosis into toxic cells, or by pharmaceutically countering the neuron-killing toxin these harmful cells almost certainly secrete. Aberrant astrocytes, “turn up in suspicious abundance in all the wrong places,” says Stanford’s Ben Barres, M.D., Ph.D., a professor of neurobiology, developmental biology, and neurology and neurological ...
01/19/17, Genetic Engineering & Biotech News

Ethypharm Buying Martindale Pharma
Ethypharm has agreed to acquire Martindale Pharma, the companies said today, in a deal the buyer said will strengthen its manufacturing capabilities and broaden its geographic reach. The price was not disclosed. Headquartered in Woburn Green, UK, Martindale Pharma is a specialty pharmaceutical company providing medicines to more than 50 countries worldwide. The company’s products focus on opioid addiction, emergency care, and sterile injectables. The combined company would have revenues of more than €300 million (about $318 million)—Ethypharm disclosed last year that it was generating more than €200 million (about $212 million) in sales—as well as what Ethypharm and Martindale Pharma assert is a solid platform for future growth. Ethypharm specializes in developing treatments for pain and addiction, as well as complex generics, marketing its products to 30 countries worldwide. Ethypharm employs 950 people, mostly in France, where the company is headquartered in Saint-Cloud, and ...
01/19/17, Genetic Engineering & Biotech News

Cytori to Acquire Azaya Platform, Cancer Candidates
Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s regenerative medicine operations. Azaya’s Protein Stabilized Liposomes™ (PSL) platform is designed to allow for high-dose delivery of potent cytotoxics with potentially lower side effects. Cytori says its research suggests that nanoparticle liposomal technology may be a useful method of delivering targeted regenerative therapies to sites of acute or chronic injury. As part of the transaction, Cytori will acquire from Azaya two oncology drug candidates that the company deems promising enough to generate what it called sizeable near-term, global licensing, and revenue opportunities. One is Azaya’s lead oncology candidate ATI-0918, an off-patent, complex, generic nanoparticle liposomal formulation of the chemotherapeutic agent doxorubicin hydrochloride, used for treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. In ...
01/19/17, Genetic Engineering & Biotech News

bioMérieux and Banyan Partner on Traumatic Brain Injury IVD
bioMérieux is making a $7 million equity investment in San Diego-based Banyan Biomarkers as part of a partnership agreement to develop and commercialize in vitro diagnostics for traumatic brain injury (TBI) using Banyan’s proprietary TBI blood biomarkers. The deal gives bioMérieux preferred rights to develop the biomarker assays for use on its VIDAS ® immunoassay platform. The partners will also explore other potential co-development prospects in TBI and other areas including critical care. Banyan was founded by scientists from the University of Florida McKnight Brain Institute to develop in vitro diagnostic tests for the detection of brain injury and neurological diseases. The firm’s TBI diagnostic platform is based on two proprietary brain-specific protein biomarkers, Banyan UCH-L1™ and Banyan GFAP™, which appear in the blood after a brain injury. Banyan’s product pipeline also includes biomarkers for stroke, depression, hypoxic ischemic encephalopathy, and neurological ICU monitoring. “We have been ...
01/19/17, Genetic Engineering & Biotech News

Altimmune, PharmAthene to Merge with Infectious Disease and Biodefense Pipeline
Immunotherapeutics firm Altimmune and biodefense therapeutics firm PharmAthene have agreed to an all stock merger to form a combined entity with four clinical-stage programs in development. Under terms of the agreement, which has been unanimously approved by the two boards of directors but has still to be approved by both firms’ shareholders, Altimmune will become a wholly owned PharmAthene subsidiary. The combined entity will retain the Altimmune name, will be owned 58.2% by Altimmune shareholders, and will be headquartered in Altimmune’s home town of Gaithersburg, MD. At closing, and subject to customary conditions, the combined firm is expected to have approximately $20 million in cash and cash commitments. The combined clinical pipeline includes Altimmune’s NasoVAX ™ , HepTcell ™ , and NasoShield ™ candidates, and PharmAthene’s SparVax ® -L anthrax vaccine. NasoVAX is an intranasal, recombinant influenza vaccine, developed using Altimmune’s RespirVec ™ platform, which is expected ...
01/19/17, Genetic Engineering & Biotech News

U.K. weighs drug rationing as NHS England's budget tightens: report
U.K. weighs drug rationing as NHS England's budget tightens: report esagonowsky Thu, 01/19/2017 - 10:40
01/19/17, Fierce Pharma

Mallinckrodt’s Acthar drama continues with $100M FTC settlement
Mallinckrodt’s Acthar drama continues with $100M FTC settlement esagonowsky Thu, 01/19/2017 - 11:45
01/19/17, Fierce Pharma

Glaxo pharma chief Hussain joins sea of departing execs, with AZ's Miels to step in
Glaxo pharma chief Hussain joins sea of departing execs, with AZ's Miels to step in chelfand Thu, 01/19/2017 - 09:58
01/19/17, Fierce Pharma

Can a $4,500 epinephrine injector challenge Mylan's scandal-plagued EpiPen?
Can a $4,500 epinephrine injector challenge Mylan's scandal-plagued EpiPen? esagonowsky Thu, 01/19/2017 - 14:42
01/19/17, Fierce Pharma

Allergan goes up against laser therapy with new rosacea treatment Rhofade
Allergan goes up against laser therapy with new rosacea treatment Rhofade chelfand Thu, 01/19/2017 - 11:04
01/19/17, Fierce Pharma

FDA has a backlog of 1,000 foreign plants that have never been inspected despite progress, GAO report finds
FDA has a backlog of 1,000 foreign plants that have never been inspected despite progress, GAO report finds epalmer Thu, 01/19/2017 - 09:55
01/19/17, Fierce Pharma

Peripheral neuropathy could be reversed by FDA-approved class of drugs
Peripheral neuropathy could be reversed by FDA-approved class of drugs aalidrus Thu, 01/19/2017 - 15:29
01/19/17, Fierce Biotech

SynteractHCR in a new phase of international hires after buyout
SynteractHCR in a new phase of international hires after buyout badams Thu, 01/19/2017 - 04:17
01/19/17, Fierce Biotech

U.K.’s path to ‘hard Brexit’ raises worries, cautious optimism
U.K.’s path to ‘hard Brexit’ raises worries, cautious optimism nick.paul.taylor Thu, 01/19/2017 - 06:48
01/19/17, Fierce Biotech

Rebooted Merrimack names Sanofi Genzyme SVP as CEO
Rebooted Merrimack names Sanofi Genzyme SVP as CEO nick.paul.taylor Thu, 01/19/2017 - 02:27
01/19/17, Fierce Biotech

Maryland biotechs PharmAthene and Novartis-backed Altimmune pen merger deal
Maryland biotechs PharmAthene and Novartis-backed Altimmune pen merger deal badams Thu, 01/19/2017 - 07:26
01/19/17, Fierce Biotech

Immunomedics talks up IMMU-132 prospects at investor day
Immunomedics talks up IMMU-132 prospects at investor day phil Thu, 01/19/2017 - 08:38
01/19/17, Fierce Biotech

Ex-GSK rare disease head moves to Genenta
Ex-GSK rare disease head moves to Genenta badams Thu, 01/19/2017 - 06:46
01/19/17, Fierce Biotech

EuroBiotech Report: Evotec founds startup, ObsEva sets IPO terms, U.K. plots path to ‘hard Brexit’ and Kitov
EuroBiotech Report: Evotec founds startup, ObsEva sets IPO terms, U.K. plots path to ‘hard Brexit’ and Kitov nick.paul.taylor Thu, 01/19/2017 - 07:38
01/19/17, Fierce Biotech

​​​​​​​EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note
​​​​​​​EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note nick.paul.taylor Thu, 01/19/2017 - 07:25
01/19/17, Fierce Biotech

Chutes & Ladders: A new global pharmaceuticals head for GSK
Chutes & Ladders: A new global pharmaceuticals head for GSK aliu Thu, 01/19/2017 - 17:23
01/19/17, Fierce Biotech

Targeting Malicious Exosomes with Gold Nanoparticles for Cancer Therapy
Exosomes are nanovesicles formed in the endosomal pathway with an important role in paracrine and autocrine cell communication. Exosomes secreted by cancer cells, malicious exosomes, have important roles in tumor microenvironment maturation and cancer progression. The knowledge of the role of exosomes in tumorigenesis prompted a new era in cancer diagnostics and therapy, taking advantage ...
01/19/17, Exosome RNA Research & Industry News

Featured Exosome Job – Scientist – Biomarker Research Program
Job Summary The Biomarker Research Program at the Houston Methodist Research Institute is led by Dario Marchetti, PhD, a renowned cancer biology expert who has made key discoveries in the biology and clinical use of circulating tumor cells (CTCs). Under Dr. Marchetti’s leadership, the Biomarker Research Program is developing multidisciplinary research programs to address clinical ...
01/19/17, Exosome RNA Research & Industry News

Seal Whiskers Can Detect Weak Water Currents
The marine predators may use the mechanosensory hairs to detect fish that are hiding motionless on the seafloor.
01/18/17, The Scientist

How Traffic Noise Affects Tree Frogs
Constant exposure to the sounds of a busy road can impact a male European tree frog’s stress levels, immune system, and vocal sac coloration, scientists show.
01/18/17, The Scientist

Journals Seek Out Preprints
With its recruitment of dedicated “preprint editors,” PLOS Genetics makes official the practice of soliciting non-peer–reviewed manuscripts posted online. 
01/18/17, The Scientist

Replication Complications
An initiative to replicate key findings in cancer biology yields a preliminary conclusion: it’s difficult.
01/18/17, The Scientist

Circular RNA – an emerging class of RNA
Circular RNA (circRNA) is a newly validated class of single-stranded RNA, ubiquitously expressed in mammalian tissues and possessing key functions including acting as microRNA sponges and as transcriptional regulators by binding to RNA-binding proteins. While independent studies confirm the expression of circRNA in various tissue types, genome-wide circRNA expression in the heart has yet to ...
01/18/17, Transcriptome Research & Industry News

Open innovation underpinning UK R&D, says ABPI
The search for new medicines in 2016 saw a continued increase in collaborative working between pharma companies and other firms, academia, and catapults, pushing further away from the closed innovation model of old, according to a new report by the Association of the British Pharmaceutical Industry.
01/18/17, PharmaTimes

EU approval for Sanofi’s diabetes combo
Sanofi-Aventis' Suliqua has been approved in the European Union expanding treatment options for people with type II diabetes.
01/18/17, PharmaTimes

Allergan, Gedeon’s fibroid drug hits PhIII targets
Allergan and Gedeon Richter are gearing up to file ulipristal acetate in the US in the second half of this year, in the hope of securing approval for the first oral treatment option for women suffering from uterine fibroids in the country.
01/18/17, PharmaTimes

Alcobra pulls plug on ADHD drug after PhIII failure
Alcobra's experimental therapy for the treatment of attention-deficit hyperactivity disorder in adults has failed to hit targets in a late-stage trial, throwing a shadow of doubt over the future of the company.
01/18/17, PharmaTimes

ABPI, BMA respond to May’s Brexit speech
Pharmaceutical industry leaders have welcomed Prime Minister Theresa May's ambition to ensure that Great Britain is "one of the best places in the world for science and innovation" post Brexit.
01/18/17, PharmaTimes

When Cancer Cells Perceive Famine, They Seek Greener Pastures
An age-old response, one deep inside the molecular networks of individual cancer cells, is so well worn that it may account for why cancer spreads and resists certain kinds of treatment. The response is the urge to migrate when resources are scarce. It is shared by cancer cells and the cells of many organisms, including fungi and bacteria. Yet in cancer cells, it has an extra twist or two. It can be activated not only by famine-like conditions, but also by other stresses, such as inflammatory signals. Essentially, cancer cells may interpret various kinds of stress as starvation and respond by activating a starvation response, part of which involves the conservation and recycling of resources, and part of which involves mobility. This response, under the scrutiny of scientists based at the Ludwig Center for Cancer Research, has yielded new details that flesh out the “why” of metastasis, and ...
01/18/17, Genetic Engineering & Biotech News

Takeda, Ovid to Co-Develop Rare Pediatric Epilepsy Candidate TAK-935
Takeda Pharmaceutical said its rare pediatric epilepsy candidate TAK-935 will be co-developed through a collaboration with Ovid Therapeutics. The value of the collaboration was not disclosed, though the companies did say Takeda received equity in Ovid and could receive payments tied to milestones in the advancement of TAK-935. Takeda and Ovid said they will split development and commercialization costs 50/50 and share in the profits 50/50 should TAK-935 come to market. Ovid will lead clinical development activities and commercialization of TAK-935 in the U.S., Europe, Canada, and Israel, while Takeda will lead commercialization in Japan, with an option to lead in Asia and other unspecified regions of the world. TAK-935 would be developed at least across rare epilepsy syndromes: “If mutually agreed, additional orphan central nervous system indications may also be pursued,” Takeda and Ovid said in a statement. Central nervous system disorders are one ...
01/18/17, Genetic Engineering & Biotech News

Sanofi's Suliqua Combination T2D Therapy Approved in the EU
Sanofi confirmed yesterday that its type 2 diabetes therapy Suliqua™ received marketing authorization in the EU. Approval in Europe follows FDA approval of the drug combination, branded Soliqua™ 100/33 in the U.S., in November 2016. Soliqua was launched in the U.S. earlier this month. Suliqua is a titratable, fixed-ratio combination of basal insulin glargine and the glucagon-like peptide 1 ( GLP-1) receptor agonist lixisenatide. EU clearance covers use of Suliqua, in combination with metformin, in adult type 2 diabetes patients, to improve glycemic control when metformin monotherapy or metformin combination therapies have not been effective. Regulatory approval in Europe was based on data from the Phase III LixiLan-O and LixiLan-L trials, which involved more than 1900 patients. Suliqua will be delivered in two prefilled SoloSTAR ® pens, to offer different dosing options. The 10-40 SoloSTAR prefilled pen will deliver 10 to 40 dose steps of insulin glargine ...
01/18/17, Genetic Engineering & Biotech News

Molecular Signaling Discovery Offers Hope for Peripheral Neuropathy Patients
Scientists at the University of California San Diego School of Medicine, with colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases, the University of Manitoba, and St. Boniface Hospital Albrechtsen Research Centre in Canada, say they have identified a molecular signaling pathway that, when blocked, promotes sensory neuron growth and prevents or reverses peripheral neuropathy in cell and rodent models of type 1 and 2 diabetes, chemotherapy-induced neuropathy, and human immunodeficiency virus (HIV)-associated neuropathy. Their findings ("Selective Antagonism of Muscarinic Receptors Is Neuroprotective in Peripheral Neuropathy") are published in the Journal of Clinical Investigation. Peripheral neuropathy is a condition resulting from damage to the peripheral nervous system. Symptoms range from numbness, tingling, and muscle weakness to severe pain, paralysis, and organ dysfunction. An estimated 20 million Americans have some form of peripheral neuropathy, which can be a symptom of many diseases, including diabetes and ...
01/18/17, Genetic Engineering & Biotech News

Microbial Nanowires Make for “Green” Electronics
The inner workings of that new cell phone or tablet could be made from bacteria in the not so distant future, as investigators from the University of Massachusetts Amherst just reported about a new type of natural wire produced by bacteria that could greatly accelerate the development of sustainable "green" conducting materials for the electronics industry. In the new study, the researchers studied microbial nanowires—protein filaments that bacteria use naturally to make electrical connections with other microbes or minerals. “Microbial nanowires are a revolutionary electronic material with substantial advantages over man-made materials,” explained senior study investigator Derek Lovley, Ph.D., professor of microbiology at UMass Amherst. “Chemically synthesizing nanowires in the lab requires toxic chemicals, high temperatures, and/or expensive metals. The energy requirements are enormous. By contrast, natural microbial nanowires can be mass-produced at room temperature from inexpensive renewable feedstocks in bioreactors with much lower energy inputs. And the ...
01/18/17, Genetic Engineering & Biotech News

Lilly to Buy CoLucid for $960M to Acquire Late-Stage Migraine Drug
Lilly has negotiated a deal to acquire Cambridge, MA-based CoLucid Pharmaceuticals for $46.5 per share in cash, which is approximately $960 million in cash. CoLucid’s flagship product is the late clinical-stage migraine therapy candidate  lasmiditan, an oral 5 -hydroxytryptamine (serotonin) receptor 1F ( 5-HT 1F ) agonist that has completed two Phase III trials and was originally licensed to CoLucid by Lilly back in 2005. The transaction is expected to close by the end of Q1 2017, subject to customary conditions. Lilly says lasmiditan will bolster its emerging pain management pipeline, which includes the calcitonin gene-related peptide (CGRP)-targeting antibody, galcanezumab (LY2951742). Galcanezumab is in Phase III development for the prevention of migraine and cluster headaches. Lilly acquired the drug from Arteaus Therapeutics in 2014. A second pain candidate, the nerve growth factor (NGF)-targeting humanized antibody tanezumab, is in Phase III development in partnership with Pfizer for multiple potential ...
01/18/17, Genetic Engineering & Biotech News

Electrogenetic Device Designed for Activating Gene Expression
Scientists from the University of Maryland (UMD) say they are working to develop an electrogenetic device to direct gene expression, an achievement that holds promise for controlling biological systems and could help shape the future of biosensors, as well as wearable and possibly implantable bio-hybrid devices. The team, led by William Bentley, Ph.D., UMD distinguished university professor and director of the university’s Robert E. Fischell Institute for Biomedical Devices, is using redox biomolecules, i.e., tiny cellular messengers that are vital to the health of all body cells, to carry electronic information to engineered bacterial cells. To do this, the group has developed a patent-pending electrogenetic device that uses an electrode and engineered cells to control how and when genes are expressed from a synthetic gene circuit. “Researchers have long used microelectronic devices embedded with biological components, such as high-throughput DNA sequencing technologies, to interrogate biology, but such ...
01/18/17, Genetic Engineering & Biotech News

Should the U.S. try M&A to save on hep C? Gilead would be a good buy, experts say
Should the U.S. try M&A to save on hep C? Gilead would be a good buy, experts say tracy Wed, 01/18/2017 - 11:26
01/18/17, Fierce Pharma

Pfizer CEO: Trump's wrong on pharma. 'Ethical' companies nothing like Shkreli or Valeant
Pfizer CEO: Trump's wrong on pharma. 'Ethical' companies nothing like Shkreli or Valeant esagonowsky Wed, 01/18/2017 - 11:15
01/18/17, Fierce Pharma

Behind-the-scenes rebates take a growing bite out of pharma sales, industry-funded study says
Behind-the-scenes rebates take a growing bite out of pharma sales, industry-funded study says esagonowsky Wed, 01/18/2017 - 16:14
01/18/17, Fierce Pharma

McKesson paying record $150M to settle with feds over opioid sales
McKesson paying record $150M to settle with feds over opioid sales epalmer Wed, 01/18/2017 - 10:25
01/18/17, Fierce Pharma

Bad news for biosim makers: FDA sets 'high bar' in interchangeability guidance
Bad news for biosim makers: FDA sets 'high bar' in interchangeability guidance esagonowsky Wed, 01/18/2017 - 09:39
01/18/17, Fierce Pharma

To win Trump's deal backing, Bayer made a new $8B-plus pledge. But how new is it?
To win Trump's deal backing, Bayer made a new $8B-plus pledge. But how new is it? chelfand Wed, 01/18/2017 - 09:05
01/18/17, Fierce Pharma

Perrigo recalling more than 162,500 tubes of acne gel
Perrigo recalling more than 162,500 tubes of acne gel epalmer Wed, 01/18/2017 - 15:30
01/18/17, Fierce Pharma

Synthetic peptide outlasts macular degeneration med Eylea in animal models
Synthetic peptide outlasts macular degeneration med Eylea in animal models aalidrus Wed, 01/18/2017 - 13:46
01/18/17, Fierce Biotech

Biogen, Siemens Healthineers to quantify MRI analysis for multiple sclerosis
Biogen, Siemens Healthineers to quantify MRI analysis for multiple sclerosis aalidrus Wed, 01/18/2017 - 11:24
01/18/17, Fierce Biotech

Bio-Rad boosts liquid biopsy chops with RainDance buy
Bio-Rad boosts liquid biopsy chops with RainDance buy aalidrus Wed, 01/18/2017 - 09:52
01/18/17, Fierce Biotech

Low clinical trial recruitment rates have poor physician communication to blame: report
Low clinical trial recruitment rates have poor physician communication to blame: report aliu Wed, 01/18/2017 - 15:52
01/18/17, Fierce Biotech

Lilly buys migraine biotech CoLucid, and the drug it outlicensed, for $960M
Lilly buys migraine biotech CoLucid, and the drug it outlicensed, for $960M badams Wed, 01/18/2017 - 07:20
01/18/17, Fierce Biotech

GeoVax draws a bead on hep B with therapeutic vaccine deal
GeoVax draws a bead on hep B with therapeutic vaccine deal phil Wed, 01/18/2017 - 08:21
01/18/17, Fierce Biotech

Next Generation: Mobile Microscope Detects DNA Sequences
A cell phone–based microscope can identify mutations in tumor tissue and image products of DNA sequencing reactions.
01/17/17, The Scientist

Number of publications citing RNA-Seq continues to increase
We’ve been keeping track of the number of papers that we can find citing RNA-Seq since 2008.  January is often a time to reflect back on the previous year, so how did the number of publications in 2016 compare to previous years?
01/17/17, Transcriptome Research & Industry News

MATQ-seq – effective detection of variation in single-cell transcriptomes
The development of single-cell RNA-seq has allowed the detection of gene expression at an anatomical resolution that is not accessible by bulk RNA-seq approaches. While single-cell RNA-seq methods have been successfully used to identify new cell types in complex tissues, technical noise in these methods is still substantial and affects researchers’ ability to detect subtle ...
01/17/17, Transcriptome Research & Industry News

Analysing Single-Cell RNA-Seq data with SeqMonk
This video looks at how you can apply some of the tools within SeqMonk to the analysis of single-cell RNA-Seq data. It goes through QC, quantitation, variation analysis, clustering and PCA so show how these can all use useful in trying to understand the structure of large RNA-Seq datasets. – Babraham Bioinformatics
01/17/17, Transcriptome Research & Industry News

SMC OKs four new therapies for NHS use in Scotland
Cost regulators in Scotland have approved NHS funding for four new medicines, expanding treatment options for lung cancer, iron excess, hepatitis C and chronic pain, but Janssen's Darzalex was rejected for multiple myeloma.
01/17/17, PharmaTimes

Ophthotech Axing 80% of Workforce after Clinical Trial Failures
Ophthotech restated today that it will slash its workforce by approximately 80% during the first half of this year, and for the first time estimated the financial effect of the cuts, a month after disclosing the failure of its Fovista ® (pegpleranib) in two Phase III trials assessing the macular degeneration candidate in a combination therapy. “The Company expects to realize estimated annualized cost savings from the reduction in personnel in the range of $25 million to $30 million starting in the third quarter of 2017,” Ophthotech said in a regulatory filing. In the filing, Ophthotech also said it will incur approximately $14.4 million of pretax charges during the first and second quarters of 2017 related to the job cuts, of which approximately $13.8 million is expected to result in future cash expenditures. “These pretax charges relate to (a) expected severance and other employee costs of ...
01/17/17, Genetic Engineering & Biotech News

MilliporeSigma Opens Meglumine Production Facility in Spain
MilliporeSigma opened a facility in Mollet des Vallès, Spain, dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.   The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. The facility in Spain is solely dedicated to the production of meglumine, thereby ensuring continuity of supply to customers as well as meeting increasing demand for the excipient, said Andrew Bulpin, head of process solutions strategic marketing and innovation at MilliporeSigma. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as active pharmaceutical ingredients (APIs), he added. "Our new facility was optimized around the manufacturing process to achieve greater efficiencies and meets the most stringent quality standards for manufacturing ...
01/17/17, Genetic Engineering & Biotech News

Evotec, MaRS Set Up Fibrocor to Develop Therapeutics Targeting Fibrosis
Toronto-based Fibrocor Therapeutics has been established by Evotec and MaRS Innovation to develop disease-modifying therapeutics against fibrotic diseases. Fibrocor launches with CND$2.8 million ($2.1 million) financing, including cash from MaRS, which is the commercialization arm for 15 of Ontario's academic institutions, including the University of Toronto and its affiliated research hospitals. Fibrocor’s scientific founders include Richard Gilbert, Ph.D., and Darren Yuen, Ph.D., at Toronto’s St. Michael Hospital, and Jeff Wrana, Ph.D., at Mount Sinai Hospital in Toronto, who have identified novel fibrosis-related targets and molecular pathways from annotated diseased and healthy human tissues. Fibrocor will work with Evotec to develop a pipeline of first-in-class therapeutics against the most promising targets and pathways. Evotec will provide all drug discovery activities and gains an equity stake in Fibrocor. A lead program has been identified, for which Fibrocor and Evotec anticipate selecting a lead candidate in 2018. "Fibrosis continues to ...
01/17/17, Genetic Engineering & Biotech News

Epigenetics Drives Pancreatic Cancer Metastasis, Potentially Reversible
A multicenter study led by investigators at Johns Hopkins University just reported on a full genomic analysis of tumor samples from a small number of people who died of pancreatic cancer. The new data suggests that epigenetic changes control how DNA operates to confer survival advantages on subsets of pancreatic cancer cells. Those advantages, the researchers say, let such cancer cells thrive in organs like the liver and lungs, which receive a sugar-rich blood supply. "What we found astonished us," remarked co-senior study investigator Andrew Feinberg, M.D., professor of epigenetics at The Johns Hopkins University and a Johns Hopkins Kimmel Cancer Center member. "Changes in genes' regulation—not in the DNA sequence of genes themselves—were the driving force behind successful metastases in our experiments, and, as far as we know, this is the first genome-wide experimental evidence for this phenomenon." Even more interestingly, the researchers reported evidence that ...
01/17/17, Genetic Engineering & Biotech News

Cognitive Genes Discovery May Lead to Novel Neurological Disease Therapies
An international team of scientists, led by Todd Lencz, Ph.D., professor at The Feinstein Institute for Medical Research at Northwell Health and Hofstra Northwell School of Medicine, say they have unlocked some of the genes responsible for cognitive ability. Dr. Lencz and fellow researchers studied the genes of 35,000 people and discovered new genetic variations related to cognitive ability. The findings bring scientists a step closer to developing new, and potentially better, treatments for cognitive disorders of the brain, such as schizophrenia and attention-deficit/hyperactivity disorder (ADHD). The findings (" GWAS Meta-Analysis Reveals Novel Loci and Genetic Correlates for General Cognitive Function: A Report from the COGENT Consortium")  are published in Molecular Psychiatry. The team of 60 international scientists, called the Cognitive Genomics Consortium (COGENT), measured brain function of the study participants through tests of learning, memory, and other components of cognitive function. In addition to zeroing in on a ...
01/17/17, Genetic Engineering & Biotech News

Biogen to Pay Forward Pharma $1.25B in Patent Dispute
Biogen said today it has agreed to pay Forward Pharma $1.25 billion in cash to secure an irrevocable license to all intellectual property owned by Forward Pharma, including patents related to Biogen’s Tecfidera ® and other multiple sclerosis treatments. The companies have come to terms on a settlement and license agreement subject to two-thirds approval by Forward Pharma’s shareholders and other customary conditions. Shareholders representing approximately 77% of Forward Pharma’s voting share capital have agreed to vote in favor of the agreement, Biogen said. Forward Pharma is expected to secure a formal approval of its shareholders at an extraordinary general meeting scheduled for February 1. “We believe this agreement will clarify and strengthen our intellectual property for Tecfidera,” Biogen CEO Michel Vounatsos said in a statement. Under specified circumstances, Biogen also agreed to pay Forward Pharma royalties on net sales of Biogen treatments for multiple ...
01/17/17, Genetic Engineering & Biotech News

Ancient Genes Return, Put Evolutionary Hypotheses to the Test
A method that has thrived in molecular evolution may prove to be less fit than a new approach. The old method, which was established 25 years ago, relies on finding “signatures of selection,” patterns suggesting that a gene chanced so quickly during its evolution that selection is likely to have been the cause. The new approach combines two recently developed technologies: statistical reconstruction of ancient gene sequences and engineering of transgenic animals. The trouble with the old approach is that it yields only circumstantial evidence. While it may find historical correlations between a gene’s rapid evolution and adaptive differences between species, signatures of selection cannot establish causation. Genes can evolve quickly for many reasons, such as chance, fluctuations in population size, or selection for functions unrelated to the environmental conditions to which the organism is thought to have adapted. To directly test the effects of a gene’s ...
01/17/17, Genetic Engineering & Biotech News

AMRA Raises $9M to Develop Cloud Technology for Body Composition Profiling
Swedish digital health firm AMRA raised $9 million in a funding round co-led by Pfizer Venture Investments and Nordic VC Novo Seeds. AMRA’s cloud-based, CE-marked AMRA ® Profiler service converts magnetic resonance images derived from a 6-minute whole-body scan into precise fat and muscle volume measurements. AMRA is now exploiting the technology to move away from more traditional body mass index (BMI) analyses and develop highly precise, individualized body composition profiles (BCPs). The firm claims BCPs will have applications in areas such as patient stratification for clinical trials, metabolic research, and potentially for predicting the development of diseases, including diabetes, cardiovascular disease, nonalcoholic steatohepatitis, and sarcopenia. The new round of investment will be used to establish an international presence, including the establishment of a U.S. subsidiary, and broaden the firm’s network of researchers and pharma companies. “Pfizer Venture Investments invests in emerging companies developing technologies that can enhance ...
01/17/17, Genetic Engineering & Biotech News

Allergan, Gedeon Richter Plan 2017 FDA Filing for Uterine Fibroids Drug Ulipristal
Allergan and partner Gedeon Richter say they anticipate filing an NDA for Allergan’s uterine fibroids therapy ulipristal acetate during the second half of 2017, on the back of positive data from a second pivotal Phase III U.S. trial. The selective progesterone receptor modulator (SPRM) is marketed by Gedeon Richter in Europe under the trade name Esmya ® and in Canada under the trade name Fibristal™, but has yet to be approved in the U.S. The Venus II study involved 432 U.S. patients, randomized to receive either 5 mg or 10 mg of ulipristal or placebo. The trial met all of its co-primary  and secondary endpoints, including percentage of patients with absence of uterine bleeding and time to absence of uterine bleeding on treatment during treatment course one. A significantly greater number of patients in both the 10-mg ulipristal group of patients (54.8%) and the 5-mg ulipristal group (42.0%) ...
01/17/17, Genetic Engineering & Biotech News

Alcobra ADHD Candidate MDX Fails Phase III Trial
Alcobra acknowledged today that its attention-deficit/hyperactivity disorder (ADHD) candidate metadoxine extended release (MDX) has failed a Phase III trial. MDX did not meet the primary endpoint of the MEASURE clinical trial, namely demonstrating a statistically significant difference from placebo in the change from baseline as measured using the Conners’ Adult ADHD Rating Scales (CAARS). “We are exceedingly disappointed with these topline results,” Alcobra president and CEO Yaron Daniely, Ph.D., MBA, said in a statement. “In the coming weeks, the Company intends to review the full dataset from MEASURE. Consequently, we will evaluate our options and communicate our strategic plan to investors.” Alcobra said its topline data analysis was conducted on MEASURE’s full analysis set, which included all of the study’s 283 randomized subjects with at least one post-baseline efficacy assessment. The failure announcement came a week after Alcobra won FDA agreement to review data collected ...
01/17/17, Genetic Engineering & Biotech News

Investigators line up Keytruda, cancer vax combo trial in glioblastoma
Investigators line up Keytruda, cancer vax combo trial in glioblastoma aliu Tue, 01/17/2017 - 15:06
01/17/17, Fierce Pharma

Experts propose Ebola 'champion group' to guide vax progress
Experts propose Ebola 'champion group' to guide vax progress esagonowsky Tue, 01/17/2017 - 16:51
01/17/17, Fierce Pharma

With Flublok at a standstill in Japan, Astellas ditches cell-culture vax collab
With Flublok at a standstill in Japan, Astellas ditches cell-culture vax collab esagonowsky Tue, 01/17/2017 - 12:41
01/17/17, Fierce Pharma

Allergan's Esmya inches closer to U.S. approval, but FDA label is key to its blockbuster fate
Allergan's Esmya inches closer to U.S. approval, but FDA label is key to its blockbuster fate chelfand Tue, 01/17/2017 - 11:27
01/17/17, Fierce Pharma

Chinese API company found faking CoAs, selling potentially tainted products
Chinese API company found faking CoAs, selling potentially tainted products epalmer Tue, 01/17/2017 - 11:42
01/17/17, Fierce Pharma

Opinion: Reuse and Reduce
Sharing leftover samples from preclinical experiments is one way biomedical researchers can make the most of animal models.
01/16/17, The Scientist

Request for contributions to a special edition on lncRNA
Research Topic – Roles of Long Non-Coding RNAs in Embryonic Development and Cellular Homeostasis Advances in genomics over the past two decades have established that more than two thirds of the eukaryotic genome is pervasively transcribed, while just >2% codes for protein. Intriguingly, the degree of organismal complexity appears proportional to the transcribed non-coding portion ...
01/16/17, lncRNA Research and Industry News

LncRNAs and miRNAs – potential biomarkers and therapeutic targets for prostate cancer
Prostate cancer (PCa) is the second lethal disease for men in western countries. Although androgen receptor (AR) signaling has been widely investigated, noncoding RNAs (ncRNAs), deficient of open reading frame, have also received considerable attention. Growing studies showed that the aberrant ncRNAs expression contributed to cell proliferation, metastasis and drug resistance in PCa. Therefore, therapeutically ...
01/16/17, lncRNA Research and Industry News

Telix Nabs Wilex's Radiolabeled mAb for Cancer Imaging and Therapeutic Use
Australian firm Telix Pharmaceuticals negotiated a worldwide license to develop and commercialize Wilex’s late clinical-stage imaging agent Redectane ® , a radiolabeled form of the monoclonal antibody girentuximab, for cancer imaging applications. The agreement also extends to developing radiolabeled girentuximab as a potential radioimmunoconjugate therapeutic for a range of tumor types. Wilex could receive up to $3.7 million in upfront and milestone payments for the imaging program, plus global sales royalties. Wilex has already completed an initial Phase III imaging study with Redectane in clear cell renal cell carcinoma (ccRCC). The firm has also been granted a special protocol assessment (SPA) by the FDA for the planned confirmatory Phase III study required to obtain marketing approval. Under terms of the deal, Telix will shoulder all future development, manufacturing, and commercialization costs for the Redectane molecular imaging program. The firm will initially invest in an improved manufacturing process for ...
01/16/17, Genetic Engineering & Biotech News

Stem Cells Broaden Potential If Deprived of miRNA
By losing a single microRNA (miRNA), pluripotent stem cells may accomplish a rare feat: they may become totipotent. That is, they may give rise not only to all the tissues of a developing embryo, but also to extraembryonic tissues—the placenta and yok sac. In short, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) may acquire the developmental potential of a zygote, or fertilized egg. miRNAs, small noncoding RNAs that do not translate into proteins, are well known for their ability to regulate gene expression. But they also influence cell fate. For example, they have been shown to maintain cell fate identity in multiple contexts. miRNAs can restrict the cell fate potential of pluripotent stem cells, and they can act as a barrier to somatic reprogramming. Now, as a result of a new study led by scientists at the University of California, Berkeley, at least one ...
01/16/17, Genetic Engineering & Biotech News

Live Long and Spicy
Aficionados of taste bud-thrashing, tongue-flaming, spicy foods may have a new reason, besides the latest chili pepper festival, to smile as researchers from the Larner College of Medicine at the University of Vermont (UVM) just published findings that showed consumption of hot red chili peppers is associated with a 13% reduction in total mortality—primarily in deaths due to heart disease or stroke.      For centuries, peppers and spices have been an integral part of many ethnic cuisines, as well as thought to be beneficial in the treatment of diseases. However, until now, only one other study—conducted in China and published in 2015—has previously examined chili pepper consumption and its association with mortality. The new study from UVM scientists corroborates the earlier study's findings. The findings from the study were published recently in PLOS ONE in an article entitled “The Association of Hot Red Chili Pepper Consumption and Mortality: A ...
01/16/17, Genetic Engineering & Biotech News

Leon and Bionpharma Partner on Nanotechnology-Based Dermatology
leon-nanodrugs and Bionpharma are partnering on the global development of a dermatological product using leon-nanodrugs’s MicroJet Reactor ® (MJR) nanotechnology platform. Under terms of the collaboration, the firms will jointly develop the product at leon’s U.S.-based contract development and manufacturing organization (CDMO) partner CoreRx, which houses the MJR platform. New Jersey-based Bionpharma will carry out future marketing and distribution of the product in the U.S. and other markets. Commenting on the agreement, Michael Mehler, Sc.D., CEO of leon-nanodrugs, said, “We are very pleased about the partnership with Bionpharma who share our vision to generate added value to therapeutic molecules through the unique attributes of our MicroJet Reactor Technology. In addition, this co-development is a key strategic step on our way to become a recognized global leader in nanotechnology-formulated pharmaceuticals.” Specialty pharmaceutical company leon-nanodrugs is exploiting its MJR nanotechnology platform to develop novel oral and parenteral drug formulations ...
01/16/17, Genetic Engineering & Biotech News

Horizon Extends CRISPR License with ERS Genomics and Inks Partnership with Solentim
Horizon Discovery extended its existing CRISPR license with ERS Genomics to give Horizon rights to use CRISPR-edited cell lines for the GMP manufacture of biotherapeutics. The Cambridge, U.K.-based company in parallel reported a 2-year collaboration with cell line development specialist Solentim to generate an automated manufacturing platform for mammalian cell genome editing. Horizon already offers comprehensive CRISPR screening services and functional genomic screens using a CRISPR/Cas9 platform. The firm claims that the agreement with ERS Genomics for the use of CRISPR-edited cell lines in biomanufacturing means that it now has rights to use CRISPR for nearly all nontherapeutic applications. Darrin Disley, Horizon CEO, commented, “Through the extension of our CRISPR license with ERS Genomics, we now have a deeper toolbox of gene-editing options, which includes our exclusive recombinant adeno-associated virus ( rAAV) technology, to apply to the generation of GMP biomanufacturing cell lines. Bioproduction was only a small ...
01/16/17, Genetic Engineering & Biotech News

Fruit Fly Alcohol Tolerance Investigated and Explained
The common fruit fly,  Drosophila melanogaster,  has evolved to have an impressive tolerance for alcohol, according to scientists. More than two decades ago, in one of the first papers using gene sequences to find signatures of natural selection, investigators hypothesized that a molecular change in an enzyme gave the fly species its superior ability to metabolize alcohol. Scientists concluded that the change they found in the alcohol dehydrogenase (ADH) protein could be the adaptation that allowed D. melanogaster to colonize ethanol-rich habitats in rotting fruit better than its nearly identical relative Drosophila simulans .  It seemed a logical conclusion that the gene sequence changes that altered amino acids in an enzyme that breaks down alcohol would be the mechanism of natural selection. However, the authors of a new paper ("Experimental Test and Refutation of a Cassic Case of Molecular Adaptation in  Drosophila melanogaster") published online in Nature Ecology & Evolution say they ...
01/16/17, Genetic Engineering & Biotech News

Bio-Rad to Acquire RainDance Technologies
Bio-Rad Laboratories has agreed to acquire RainDance Technologies for an undisclosed price, the companies said today. “The company's droplet-based solutions will extend our reach into next-generation sequencing (NGS) applications and strengthen our position in the area of Droplet Digital™ PCR,” Bio-Rad president and CEO Norman Schwartz said in a statement. “We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications.” Headquartered in Billerica, MA, RainDance has specialized in the development and application of droplet microfluidic technology, with applications in life science research and clinical research.  RainDance markets products for digital PCR and sample enrichment for NGS and has demonstrated the feasibility of using its droplet technology for digital enzyme-linked immunosorbent assay (ELISA), linked-read NGS, single-cell analysis, compound screening for therapeutics, and enzyme evolution. Since its founding in 2004, RainDance ...
01/16/17, Genetic Engineering & Biotech News

Urine Exosomes – An Emerging Trove of Biomarkers
Exosomes are released by most cells and can be isolated from all biofluids including urine. Exosomes are small vesicles formed as part of the endosomal pathway that contain cellular material surrounded by a lipid bilayer that can be traced to the plasma membrane. Exosomes are potentially a more targeted source of material for biomarker discovery ...
01/16/17, Exosome RNA Research & Industry News

Microfluidic approaches for isolation, detection, and characterization of extracellular vesicles
Extracellular vesicles (EVs) are cell-derived vesicles present in body fluids that play an essential role in various cellular processes, such as intercellular communication, inflammation, cellular homeostasis, survival, transport, and regeneration. Their isolation and analysis from body fluids have a great clinical potential to provide information on a variety of disease states such as cancer, cardiovascular ...
01/16/17, Exosome RNA Research & Industry News

Pig gene advance could boost sperm stocks from prized animals
Gene-editing techniques could help to improve stocks of farmed pigs by boosting supplies of sperm from prized sires. Scientists have created male pigs that could be used as surrogates capable of producing sperm that contains the genetic blueprint of sought-after pigs. Researchers say the breakthrough will allow farmers to preserve sperm from prized animals in perpetuity.
01/13/17, ScienceDaily

Study: MicroRNA, Retroviruses Coordinate to Influence Pluripotency
Removing a specific miRNA from stem cells may induce the expression of endogenous retroviruses that enable the cells to form extra-embryonic lineages.
01/13/17, The Scientist

How Plant-Soil Feedback Affects Ecological Diversity
Researchers examine how underground microbes and nutrients affect plant populations.
01/13/17, The Scientist

Oliver Smithies, Technologist Behind Knockout Mice, Dies
The Nobel laureate and Lasker awardee developed tools that facilitated decades of genetics research, including starch gel electrophoresis and gene targeting.
01/13/17, The Scientist

KTCNlncDB – a first platform to investigate lncRNAs expressed in human keratoconus and non-keratoconus corneas
Keratoconus (KTCN, OMIM 148300) is a degenerative eye disorder characterized by progressive stromal thinning that leads to a conical shape of the cornea, resulting in optical aberrations and even loss of visual function. The biochemical background of the disease is poorly understood, which motivated researchers from the Medical University of Warsaw to perform RNA-Seq experiment, ...
01/13/17, lncRNA Research and Industry News

Effective knockdown of Drosophila long noncoding RNAs by CRISPR interference.
Ji-Long Liu (Univ Oxford) presents ‘Effective knockdown of Drosophila long noncoding RNAs by CRISPR interference.’ A presentation at the ‘Techniques & Resources’ session of the Annual Drosophila Research Conference at The Allied Genetics Conference, July 13-17, 2016, Orlando, Florida. Read the abstract: http://www.genetics-gsa.org/genetics/… For more presentations from #TAGC16 visit: http://www.genetics-gsa.org/tagcvideos or browse the playlists at: ...
01/13/17, lncRNA Research and Industry News

Nivalis CEO and CMO Step Down as Firm Slashes Workforce to Save Cash
Cystic fibrosis therapeutics firm Nivalis Therapeutics is axing 25 of its 30-strong workforce in a bid to save funds after it was announced late last year that lead candidate cavosonstat (N91115) failed to meet its primary endpoint in a Phase II study.  Jon Congleton, president and CEO, and David Rodman, M.D., CMO and evp for discovery, will be among those stepping down. The job cuts, announced yesterday, will cost Nivalis about $3 million in severance pay and leave the company with an estimated $45 to $47 million in net cash for potential strategic alternatives.  The firm had announced in early January that it was exploring and reviewing a range of strategic alternatives. At that time it also confirmed that a second, ongoing Phase II cavosonstat study, SNO-7, would continue, The trial is evaluating the cystic fibrosis transmembrane conductance regulator (CFTR) stabilizer in CF patients taking Kalydeco™ (ivacaftor) and ...
01/13/17, Genetic Engineering & Biotech News

Key Protein Involved in Cellular Aging Identified
Investigators at the Scripps Research Institute (TSRI) say they have discovered a protein that fine-tunes the cellular clock involved in aging. Named TZAP, for telomeric zinc finger-associated protein, it binds the ends of chromosomes and determines how long telomeres can be. Understanding telomere length is crucial because telomeres set the lifespan of cells in the body, dictating critical processes such as aging and the incidence of cancer. "Telomeres represent the clock of a cell," said TSRI associate professor Eros Lazzerini Denchi, Ph.D., corresponding author of the new study ("TZAP: A Telomere-Associated Protein Involved in Telomere Length Control"), published online in Science. "You are born with telomeres of a certain length, and every time a cell divides, it loses a little bit of the telomere. Once the telomere is too short, the cell cannot divide anymore." Researchers are curious whether lengthening telomeres could slow aging, and many scientists have looked ...
01/13/17, Genetic Engineering & Biotech News

Enhancer RNA Reaches Out to Help DNA Loosen Up
There are times when chromatin, the more or less tightly packed complex of DNA and histone protein, can be induced to let its freak flags fly. These freak flags are acetyl groups, and when they fly, they signal that gene-coding regions are primed to hang loose—and indulge in profuse expression. This form of gene activation may depend on a mechanism involving not just flamboyant acetyl groups, but also unassuming enhancer RNAs (eRNAs), molecules that are transcribed from DNA but do not code for protein. eRNAs are content to stay in the background, where they subtly facilitate the protein-coding regions of the genome. Although eRNAs are modest, they have been brought into the spotlight by scientists based at the University of Pennsylvania School of Medicine. According to these scientists, eRNA can bind to CREB-binding protein (CBP), a transcription co-activator, to stimulate acetylation and, ultimately, gene expression. This ...
01/13/17, Genetic Engineering & Biotech News

Dengue-Resistant Mosquitoes Have Arrived
One can only imagine the pain and morbidity associated with a disease that is colloquially referred to in many parts of the world as “breakbone fever.” Yet, for the nearly 400 million people infected annually with the dengue virus (DENV), imagination need not be applied as they have experienced the reality of this painful and potentially lethal virus. With no viable vaccine currently in use and a death toll of more than 20,000 per year, mostly children, researchers have continually searched for potentially methods to reduce or eliminate DENV transmission.   Now, investigators from the Johns Hopkins Bloomberg School of Public Health have successfully engineered mosquitoes to resist infection from DENV. The researchers found that it was possible, in the lab, to boost the Aedes aegypti mosquito's natural ability to fight the DENV as a first step toward suppressing its capacity to spread the disease. The researchers are optimistic ...
01/13/17, Genetic Engineering & Biotech News

Aerie Pharmaceuticals Eyes First Manufacturing Plant in Ireland
Aerie Pharmaceuticals plans to build a new €25 million ($26.5 million) manufacturing plant that will initially employ 50 people at the recently built IDA Advanced Technology Building in Athlone, Ireland, the country’s economic development agency IDA Ireland said today. Aerie has entered into lease talks with IDA Ireland to establish the company’s first manufacturing plant, which is expected to produce commercial supplies for its two lead product candidates—Rhopressa™ (netarsudil ophthalmic solution) 0.02% and Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of Rhopressa and the widely prescribed prostaglandin analog (PGA) latanoprost. Both candidates are once-daily intraocular pressure (IOP)-lowering therapies with novel mechanisms of action designed to treat patients with glaucoma or ocular hypertension. Should Rhopressa and Roclatan win approval, the candidates are expected to offer the first new mechanisms of action for treatment of patients with glaucoma in some 20 years. Aerie originally submitted an NDA ...
01/13/17, Genetic Engineering & Biotech News

Exosomes – Key mediators of metastasis and pre-metastatic niche formation
While tumour cells are classically known to communicate via direct cell-to-cell contact and the secretion of soluble protein-based factors such as cytokines and growth factors, alternative novel mechanisms that promote tumour progression have recently emerged. Now, new critical components of the secretome thought to be involved in tumour progression are exosomes, small vesicles of endocytic ...
01/13/17, Exosome RNA Research & Industry News

CloudHealth Genomics Presents HealthySeq, the World’s First Whole Genome Sequencing Liquid Biopsy Test for Healthy Individuals
CloudHealth Genomics, a leading genomics-based precision medicine solutions provider in China, presented data today for the launch of HealthySeq, the world first whole genome next generation sequencing (NGS)-based liquid biopsy test designed to establish a genomic baseline for healthy individuals for a scientific health/wellness management perspective at the 9th Annual Biotech Showcase™, which occurs concurrently ...
01/13/17, Exosome RNA Research & Industry News

A Path to the Standardiation of Exosome Isolation & NGS Characterization for Complex Disease Studies
A Path to the Standardiation of Exosome Isolation and NGS Characterization for Complex Disease Studies with Dr. Chad Schwartz.
01/12/17, Exosome RNA Research & Industry News

A biosensor is able to detect tumors at early stages
IMAGE: Tumor suppressor p53 trimer and DNA fragment. Credit: Cho, Y., Gorina, S., Jeffrey, P.D., Pavletich, N.P.; Astrojan. Before a malignant tumor is developed, the immune system tries to fight against proteins that are altered during their formation, producing certain cancer antibodies. A biosensor developed by scientists from the Complutense University of Madrid has been able ...
01/12/17, Exosome RNA Research & Industry News

Catching CRISPR in action: First all-atom simulation of genome editing in action
Scientists have performed the first all-atom molecular dynamics simulations of Cas9-catalyzed DNA cleavage in action. The simulations shed light on the process of Cas9 genome editing and helped resolve controversies about specific aspects of the cutting.
01/11/17, ScienceDaily

New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials
NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.
01/11/17, National Institutes of Health

Exploring the Epigenetics of Ethnicity
Researchers attempt to estimate how much of the human genome’s methylation patterns can be attributed to genetic ancestry.
01/11/17, The Scientist

LincSNP 2.0 – an updated database for linking disease-associated SNPs to human long non-coding RNAs
Researchers from Harbin Medical University describe LincSNP 2.0, an updated database that is used specifically to store and annotate disease-associated single nucleotide polymorphisms (SNPs) in human long non-coding RNAs (lncRNAs) and their transcription factor binding sites (TFBSs). In LincSNP 2.0, the researchers have updated the database with more data and several new features, including: expanding ...
01/11/17, lncRNA Research and Industry News

Johns Hopkins researchers identify new biological target for treating spinal muscular atrophy
Johns Hopkins researchers along with academic and drug industry investigators say they have identified a new biological target for treating spinal muscular atrophy. They report they have evidence that an experimental medicine aimed at this target works as a “booster” in conjunction with a drug called nusinersen that was recently FDA-approved to improve symptoms of ...
01/11/17, lncRNA Research and Industry News

For viral predators of bacteria, sensitivity can be contagious
Scientists have shown for the first time how bacteria with resistance to a viral predator can become susceptible to it after spending time in the company of other susceptible or 'sensitive' bacteria. This 'contagious' sensitivity, enabling bacteriophage invasion into previously resistant cells, could have a major impact on the transfer of antibiotic resistance genes among bacteria.
01/10/17, ScienceDaily

Neural Mechanism Links Alcohol Consumption to Binge Eating
Ethanol triggers starvation-activated neurons, leading mice to overeat. 
01/10/17, The Scientist

As the Brain Ages, Glial-Cell Gene Expression Changes Most
Researchers describe how gene expression in different human brain regions is altered with age.
01/10/17, The Scientist

Visualizing the secondary and tertiary architectural domains of lncRNA RepA
Long noncoding RNAs (lncRNAs) are important for gene expression, but little is known about their structures. RepA is a 1.6-kb mouse lncRNA comprising the same sequence as the 5′ region of Xist, including A and F repeats. It has been proposed to facilitate the initiation and spread of X-chromosome inactivation, although its exact role is ...
01/10/17, lncRNA Research and Industry News

FEELnc – a tool for long non-coding RNA annotation
Whole transcriptome sequencing (RNA-seq) has become a standard for cataloguing and monitoring RNA populations. One of the main bottlenecks, however, is to correctly identify the different classes of RNAs among the plethora of reconstructed transcripts, particularly those that will be translated (mRNAs) from the class of long non-coding RNAs (lncRNAs). Here, researchers from University Rennes1 ...
01/10/17, lncRNA Research and Industry News

Biomarker in blood may help predict recovery time for sports concussions
Blood protein tau could be an important new clinical biomarker to better identify athletes who need more recovery time.
01/06/17, National Institutes of Health

Do Preprints Belong in Grant Applications?
As the NIH questions the place of preprints in grant applications, the U.K.’s MRC encourages scientists to submit non-peer–reviewed works for consideration.
01/06/17, The Scientist

Next Generation: Biocompatible Microdevices
A new fabrication strategy enables scientists to manufacture fully biocompatible, implantable medical devices. 
01/06/17, The Scientist

Scientists learn how to ramp up microbes' ability to make memories
Researchers have identified a mutation that prompts bacterial cells to acquire genetic memories 100 times more frequently than they do naturally. This discovery provides a powerful research tool and could bring scientists one step closer to developing DNA-based data storage devices.
01/05/17, ScienceDaily

NIH-sponsored expert panel issues clinical guidelines to prevent peanut allergy
Recommendations focus on introducing peanut-containing foods to infants.
01/05/17, National Institutes of Health

How Hummingbirds Sense Movement While Hovering
A visual motion-sensing brain region found in all four-limbed vertebrates displays unique properties in Anna’s hummingbirds.
01/05/17, The Scientist

Forms of Alzheimer?s May Display Unique Plaque Structures
A study shows that different fibril formations in the brains of deceased patients seem to correlate with various Alzheimer’s disease subtypes. 
01/04/17, The Scientist

Sex hormone-sensitive gene complex linked to premenstrual mood disorder
Dysregulated cellular response to estrogen and progesterone suspected.
01/03/17, National Institutes of Health

Parental obesity linked to delays in child development, NIH study suggests
Children of obese mothers were more likely to fail tests of fine motor skill.
01/03/17, National Institutes of Health

Natural Selection Kept Neanderthal DNA in Modern Humans
Interbreeding with Neanderthals appears to have reintroduced genetic sequences related to innate immunity that had been lost as humans migrated out of Africa. 
12/29/16, The Scientist

Q&A: What?s Next for PLOS
A conversation with outgoing Chief Executive Officer Elizabeth Marincola
12/27/16, The Scientist

The Scientist?s Year in Review
Twelve months of news and features
12/27/16, The Scientist

Visualizing gene expression with MRI
A cellular gatekeeper for water molecules finds new use in magnetic resonance imaging, a new report explains.
12/23/16, ScienceDaily

Behavior Brief
A round-up of recent discoveries in behavior research
12/23/16, The Scientist

Opinion: Aging, Not a Disease
A response to “Opinion: Aging, Just Another Disease” 
12/23/16, The Scientist

Life Science Controversies of 2016
This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.
12/23/16, The Scientist

Those We Lost in 2016
The scientific community bid farewell to several luminaries this year.
12/23/16, The Scientist

Exome Study Reveals Novel Disease-Linked Alleles
By combining whole-exome sequencing data with longitudinal electronic health record information for 50,000 individuals, researchers have identified novel disease associations.
12/22/16, The Scientist

New CRISPR-Cas Enzymes Discovered
A metagenomics analysis finds Cas9 in archaea for the first time, along with two previously unknown Cas nucleases from bacteria.
12/22/16, The Scientist

Best of Multimedia 2016
Editors’ picks of the year’s best in The Scientist infographics, slideshows, and videos
12/21/16, The Scientist

Top 10 Retractions of 2016
A look at this year’s most memorable retractions
12/21/16, The Scientist

Opinion: A Tale of Two Hemispheres
Studying savant-like behaviors in birds could help researchers better understand autism spectrum disorders.
12/20/16, The Scientist

TS Picks: Life Science Photos of the Year
Selected Images of the Day
12/20/16, The Scientist

The Year in Zika
Scientists advanced the battle against Zika in 2016, conducting basic research to better understand and detect the pathogen while preventing its spread.
12/19/16, The Scientist

Speaking of Science: 2016
Selected quotes from an eventful year
12/19/16, The Scientist

US Postdocs Grapple with Salary Changes
Postdocs nationwide were set to have an increased minimum salary or become eligible for overtime pay until a court injunction halted new Department of Labor regulations.
12/16/16, The Scientist

Opinion: The Scientist?s Scarlet Letter
Managing privacy protections and expectations in a misconduct proceeding
12/16/16, The Scientist

New Species of 2016
From a new Tyrannosaurus and many other dinosaurs to all of the living species named this year, researchers continue to chip away at the planet’s unknown biodiversity.
12/16/16, The Scientist

Top Technical Advances 2016
The year’s most impressive achievements include methods to watch translation in cells, trace cell fates, avoid mitochondrial mutations, edit DNA, and build antibiotics from scratch.
12/15/16, The Scientist

Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
New approaches to treating cancer have shown great promise, but they also come with serious risks that give us cause for concern.
12/15/16, The Scientist

Nearly 500 lncRNAs Needed For Cell Growth Identified
Using a modified CRISPR approach, scientists shed light on the diversity and function of 499 long noncoding RNAs.
12/15/16, The Scientist

Keeping CRISPR in Check
In bacteriophage genomes, researchers find three anti-CRISPR proteins that naturally inhibit CRISPR-Cas9 in one bacterial species and can do the same in human cells. 
12/14/16, The Scientist

Self-Editing Genetic Barcodes
Scientists create a CRISPR-based, self-editing cellular–barcoding system for extensive molecular recording.
12/14/16, The Scientist

TS 2016 Gift Guide
Sciencey gifts for the science-minded giver
12/13/16, The Scientist

Induced Pluripotent Stem Cells Show Signs of Donor Age
iPSCs created through the reprogramming of human somatic cells retain genomic marks of the donor’s age.
12/12/16, The Scientist

3-D Models Capture Endangered Species Before They Go Extinct
With the Beastcam, conservation biologists can capture the minute details of endangered species in stunning 3-D models.
12/09/16, The Scientist

Could Critical Incident Reporting Fix Preclinical Research?
Scientists propose a modified critical incident reporting system to help combat the reproducibility crisis.
12/09/16, The Scientist

An anti-CRISPR for gene editing
Researchers have discovered a way to program cells to inhibit CRISPR-Cas9 activity. 'Anti-CRISPR' proteins had previously been isolated from viruses that infect bacteria, but now scientists report three families of proteins that turn off CRISPR systems specifically used for gene editing. The work offers a new strategy to prevent CRISPR-Cas9 technology from making unwanted changes.
12/08/16, ScienceDaily

Phages Carry Antibiotic Resistance Genes
Researchers find evidence of antibiotic resistance genes in the DNA of viruses that infect bacteria.
12/08/16, The Scientist

Transforming plant cells from generalists to specialists
As a plant extends its roots into the soil, the cells that form at their tips assume different roles, from transporting water to sensing gravity. A study points to one way by which these newly-formed cells take on their special identities, despite containing the same DNA. Researchers have identified a set of DNA-binding proteins in Arabidopsis roots that help precursor cells selectively read different parts of the same genetic script.
12/07/16, ScienceDaily

PubPeer Wins Appeal on Anonymous Comments
The Michigan Court of Appeals rules that anonymous commenters on the post-publication peer review website are protected under the First Amendment.
12/07/16, The Scientist

Toward Treating Alzheimer?s Disease with Brain Waves
In a mouse model, researchers mitigated three Alzheimer’s disease–associated symptoms by stimulating gamma waves with light.
12/07/16, The Scientist

Highly efficient genome engineering in flowering plants
Plant biologists have developed a genome editing method to knockout target genes in a model plant with high efficiency. The team reports a new CRISPR/Cas9 vector for the model plant that can strongly induce inheritable mutations. This method is expected to become a powerful molecular tool for genome engineering in various plant species.
12/05/16, ScienceDaily

Sun Sentinel: Ocean Ridge Biosciences expands to 5,400-square foot facility
Read More...
12/05/16, ORB Company News

Modifying a live virus in a vaccine to be just strong enough
By genetically tweaking the constituent live virus, scientists have created a vaccine against influenza in which the virus is capable of activating the immune system but cannot replicate in healthy cells -- an approach that may become more widely used for generating live virus vaccines adapted to other viruses.
12/01/16, ScienceDaily

Pelican Newspaper: Gene profiling at Ocean Ridge Biosciences to unlock mysteries of the human body
Read More...
11/25/16, ORB Company News

Researchers create synthetic cells to isolate genetic circuits
Encapsulating molecular components in artificial membranes offers more flexibility in designing circuits, report researchers.
11/14/16, ScienceDaily

Biologists give bacteria thermostat controls
A new helper in the fight against cancer and other diseases of the gut may be genetically altered bacteria that release medicines to tumors or the gut, report scientists.
11/14/16, ScienceDaily

People who know about genetically modified food agree with science: They're safe
People who know about genetically modified food agree with science, that they're safe. On the other hand, those who know plenty about global warming are cautious about the science that says humans cause the phenomenon, a new study shows. Furthermore, the study showed some people still make what researchers call "illusionary correlations," such as "genetically modified foods cause autism."
11/09/16, ScienceDaily

Model predicts elimination of GMO crops would cause hike in greenhouse gas emissions
A global ban on genetically modified crops would raise food prices and add the equivalent of nearly a billion tons of carbon dioxide to the atmosphere, a study shows.
11/08/16, ScienceDaily

Changing cell behavior could boost biofuels, medicine
A computer scientist has developed a way to coax cells to do natural things under unnatural circumstances, which could be useful for stem cell research, gene therapy and biofuel production. A research team has designed an algorithm, called NetSurgeon, that recommends genes to surgically remove from a cell’s genome to force it to perform a normal activity in a different environment or circumstance.
11/07/16, ScienceDaily

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
Read More...
11/07/16, ORB Company News

Chemists create clusters of organelles by mimicking nature
Scientists have succeeded in organizing spherical compartments into clusters mimicking the way natural organelles would create complex structures. They managed to connect the synthetic compartments by creating bridges made of DNA between them. This represents an important step towards the realization of so-called molecular factories.
11/02/16, ScienceDaily

Scientists flip molecular switches to distinguish closely related immune cell populations
The cornerstone of genetics is the loss-of-function experiment. In short, this means that to figure out what exactly gene X is doing in a tissue of interest—be it developing brain cells or a pancreatic tumor—you somehow cut out, switch off or otherwise destroy gene X in that tissue and then watch what happens. That genetic litmus test has been applied since before people even knew the chemical DNA is what makes up genes. What has changed radically are the tools used by biologists to inactivate a gene.
11/01/16, ScienceDaily

NIH researchers unveil new wound-healing role for protein-folding gene in mice
Bethesda, Md., Thur., October 27, 2016 - National Institutes of Health researchers have identified a novel role for a gene known as heat shock protein 60 (Hsp60), finding that it is critical in tissue regeneration and wound healing. Researchers found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model. The study was published online today, October 27, in the journal npj Regenerative Medicine.


10/27/16, National Human Genome Research Institute

Gene therapy shows promise for treating Niemann-Pick disease type C1�
Bethesda, Md., Wed., October 26, 2016 - or the first time, National Institutes of Health (NIH) researchers have demonstrated in mice that gene therapy may be the best method for correcting the single faulty gene that causes Niemann-Pick disease, type C1 (NPC1). The gene therapy involved inserting a functional copy of the NPC1 gene into mice with the disease; the treated animals were then found to have less severe NPC1 symptoms. The study, led by researchers at NIH's National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, was published Oct. 26, 2016, in the journal Human Molecular Genetics.


10/26/16, National Human Genome Research Institute

Celebration to Commemorate Ocean Ridge Biosciences Re-Opening at New Facility
Friday, November 18th, 2016 from 5:00PM to 8:00PM at 394 SW 12th Avenue, Deerfield Beach, FL.
Full Press Release...

10/25/16, ORB Company News

Tobacco plants engineered to manufacture high yields of malaria drug
In 2015, the Nobel Prize in Physiology or Medicine was awarded in part for the discovery of artemisinin, a plant-derived compound that's proven to be a lifesaver in treating malaria. Yet many people who need the drug are not able to access it, in part because it's difficult to grow the plant that is the compound's source. Now, research has shown that tobacco plants can be engineered to manufacture the drug at therapeutic levels.
10/20/16, ScienceDaily

Antifungal RNA spray could help fight barley crop disease
Spraying barley crops with RNA molecules that inhibit fungus growth could help protect the plants against disease, according to a new study. Plant diseases caused by fungi that grow on crops seriously threaten the world's food supply, and fungi can develop resistance to traditional pesticides.
10/13/16, ScienceDaily

Researchers modify yeast to show how plants respond to a key hormone
Researchers have developed a novel toolkit based on modified yeast cells to tease out how plant genes and proteins respond to auxin, the most ubiquitous plant hormone. Their system allowed them to decode auxin's basic effects on a diverse family of plant genes.
09/27/16, ScienceDaily

New switch decides between genome repair, death of cells
The genetic information of every cell is encoded in the sequence of the DNA double helix. Double strand breaks in the DNA, which can be induced by radiation, are a dangerous threat to the cells, and if not properly repaired can lead to cancer. Damaged cells need to decide whether the breaks can be fixed or whether they should be removed by a cellular suicide program called “apoptosis” before initiating cancer.
09/27/16, ScienceDaily

Shedding light on the limits of the expanded genetic code
In 2014, scientists made a huge news splash when they reported the ability to grow bacteria with an expanded genetic code. Critics feared the rise of unnatural creatures; others appreciated the therapeutic potential of the development. Now, researchers have found that the expanded code might have an unforeseen limitation. A study reports that these novel components can damage cells when they are exposed to light.
09/15/16, ScienceDaily

Researcher calls for animal-human embryo research to proceed, but with strong animal protections
A researcher calls for animal-human embryo research to proceed – but only with strong animal protections in place. So-called "chimera" research raises the hope of producing human organs in genetically modified large animals, such as pigs and sheep, offering a potential solution to the persistent shortage of human organs for transplantation.
09/14/16, ScienceDaily

Breakthrough in genetic modification of grains
Genetic modification of plants might be controversial in commercial applications, but it is undeniably useful for research purposes. Despite years of effort, it has been remarkably difficult to develop efficient methods for transformation of grain crops. New work reports on a method to genetically modify maize and other grains.
09/12/16, ScienceDaily

Study reveals how ionising radiation damages DNA and causes cancer

For the first time, researchers from the Wellcome Trust Sanger Institute and their collaborators have been able to identify in human cancers two characteristic patterns of DNA damage caused by ionising radiation. These fingerprint patterns may now enable doctors to identify which tumours have been caused by radiation, and investigate if they should be treated differently.


09/12/16, BiologyNews.net

Human kidney progenitors isolated, offering new clues to cell renewal

In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells. Their results, published online in the journal Stem Cell Translational Medicine, will help scientists understand how these progenitor cells become renal cells in the developing fetus, and possibly offer a future way to foster renal regeneration after chronic kidney failure or acute injury.


09/12/16, BiologyNews.net

Protein found that initiates DNA repair
A research team has discovered a protein that may serve as a first responder that sets in motion a cascade of molecular activity to repair damaged DNA.
09/09/16, ScienceDaily

Giraffes more speciose than expected

Scientists from the Senckenberg and the Giraffe Conservation Foundation have analysed the genetic relationships of all major populations of giraffe in the wild. The large study on the genetic makeup of giraffe, published today in Current Biology, shows that there are four distinct giraffe species. Until now, only one giraffe species had been recognized. The unexpected results are based on analyses using several nuclear marker genes of more than 100 animals. The new insights are set to improve protection efforts of these endangered animals in Africa.


09/09/16, BiologyNews.net

New 'Trojan horse' antibody strategy shows promise against all Ebola viruses

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus. Two antibodies developed with this strategy blocked the invasion of human cells by all five ebolaviruses, and one of them protected mice exposed to lethal doses of Ebola Zaire and Sudan, the two most dangerous. The team included scientists from Albert Einstein College of Medicine, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Integrated Biotherapeutics, Vanderbilt University Medical Center, and The Scripps Research Institute.


09/09/16, BiologyNews.net

Was a researcher just served a world first CRISPR meal?
For (probably) the first time ever, plants modified with the "genetic scissors" CRISPR-Cas9 has been cultivated, harvested and cooked. D professor in Plant Cell and Molecular Biology served pasta with "CRISPRy" vegetable fry to a radio reporter. Although the meal only fed two people, it was still the first step towards a future where science can better provide farmers and consumers across the world with healthy, beautiful and hardy plants.
09/05/16, ScienceDaily

Brain circuit that drives sleep-wake states, sleep-preparation behavior is identified

Stanford University School of Medicine scientists have identified a brain circuit that's indispensable to the sleep-wake cycle. This same circuit is also a key component of the reward system, an archipelago of interconnected brain clusters crucial to promoting behavior necessary for animals, including humans, to survive and reproduce.


09/05/16, BiologyNews.net

Biochemists' discovery could lead to vaccine against 'flesh-eating' bacteria

Biochemists at the University of California San Diego have uncovered patterns in the outer protein coat of group A Streptococcus that could finally lead to a vaccine against this highly infectious bacteria--responsible for more than 500,000 deaths a year, including toxic shock syndrome and necrotizing fasciitis or "flesh-eating disease."


09/05/16, BiologyNews.net

New genus of bacteria found living inside hydraulic fracturing wells


Ohio State University researchers and their colleagues have identified a new genus of bacteria living inside hydraulic fracturing wells.
Researchers analyzing the genomes of microorganisms living in shale oil and gas wells have found evidence of sustainable ecosystems taking hold there--populated in part by a never-before-seen genus of bacteria they have dubbed "Frackibacter."


09/05/16, BiologyNews.net

Forensic DNA analysis checks the origin of cultured cells
Cell lines are cultured cells that are commonly used in medical research. New results show that such cells are not always what they are assumed to be. Using genetic analyses, the researchers showed that a commonly used cell line that was established almost 50 years ago does not originate from the patient it is claimed to stem from.
08/31/16, ScienceDaily

More tomatoes, faster: Accelerating tomato engineering
While looking for ways to make tomatoes and other crop plants more productive, researchers developed a way to cut the time required to modify a tomato's genes by six weeks. The improvement will save on money and resources while accelerating tomato research.
08/30/16, ScienceDaily

More tomatoes, faster: Accelerating tomato engineering


A researcher transfers tomato plantlets from a plate of regeneration medium.
Tomatoes are already an ideal model species for plant research, but scientists at the Boyce Thompson Institute (BTI) just made them even more useful by cutting the time required to modify their genes by six weeks.


08/30/16, BiologyNews.net

New species of pterosaur discovered in Patagonia


This is a paleoartist's reconstruction of a ptesosaur.
Scientists today announced the discovery of a new species of pterosaur from the Patagonia region of South America. The cranial remains were in an excellent state of preservation and belonged to a new species of pterosaur from the Early Jurassic. The researchers have named this new species 'Allkauren koi' from the native Tehuelche word 'all' for 'brain', and 'karuen' for 'ancient'.


08/30/16, BiologyNews.net

Study finds shark fins & meat contain high levels of neurotoxins linked to Alzheimer's disease


Cyanobacterial neurotoxin β-N-methylamino-L-alanine (BMAA) and Mercury are detected in sharks from the Atlantic and Pacific Oceans.
In a new study, University of Miami (UM) scientists found high concentrations of toxins linked to neurodegenerative diseases in the fins and muscles of 10 species of sharks. The research team suggests that restricting consumption of sharks can have positive health benefits for consumers and for shark conservation, since several of the sharks analyzed in the study are threatened with extinction due to overfishing.


08/29/16, BiologyNews.net

Artificial intelligence expedites breast cancer risk prediction

Researchers at Houston Methodist have developed an artificial intelligence (AI) software that reliably interprets mammograms, assisting doctors with a quick and accurate prediction of breast cancer risk. According to a new study published in Cancer (early online Aug. 29), the computer software intuitively translates patient charts into diagnostic information at 30 times human speed and with 99 percent accuracy.


08/29/16, BiologyNews.net

Purest yet liver-like cells generated from induced pluripotent stem cells


This image shows induced pluripotent stem cells expressing a characteristic cell surface protein called SSEA4 (green).
A research team including developmental biologist Stephen A. Duncan, D. Phil., SmartStateTM Chair of Regenerative Medicine at the Medical University of South Carolina (MUSC), has found a better way to purify liver cells made from induced pluripotent stem cells (iPSCs). Their efforts, published August 25, 2016 in Stem Cell Reports, will aid studies of liver disease for the National Heart, Lung, and Blood Institute (NHLBI)'s $80 million Next Generation Genetic Association Studies (Next Gen) Program. The University of Minnesota (Minneapolis) and the Medical College of Wisconsin (Milwaukee) contributed to the study.


08/29/16, BiologyNews.net

Yale team discovers how Zika virus causes fetal brain damage

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal Cell Reports.


08/25/16, BiologyNews.net

In some genetic cases of microcephaly, stem cells fail to launch

In a very severe, genetic form of microcephaly, stem cells in the brain fail to divide, according to a new Columbia University Medical Center study that may provide important clues to understanding how the Zika virus affects the developing brain.


08/25/16, BiologyNews.net

NIH researchers discover otulipenia, a new inflammatory disease
Bethesda, Md., Mon., August 22, 2016 -�National Institutes of Health researchers have discovered a rare and sometimes lethal inflammatory disease - otulipenia - that primarily affects young children. It is caused by the malfunction of OTULIN, a single gene on chromosome 5. They also identified anti-inflammatory treatments to ease some of the patients' symptoms: fever, skin rashes, diarrhea, joint pain and overall failure to grow or thrive. Read more in the Aug. 22, early edition of the Proceedings of the National Academy of Sciences.


08/22/16, National Human Genome Research Institute

Synthetic biology: Engineering a chemical switch into a light-driven proton pump
Synthetic biology is an emerging and rapidly evolving engineering discipline. Now scientists have engineered a chemically switchable version of the light-driven proton pump proteorhodopsin -- an essential tool for efficiently powering molecular factories and synthetic cells.
08/09/16, ScienceDaily

Scientists program cells to remember and respond to series of stimuli
Engineers have programmed cells to remember and respond to events. This approach to circuit design enables scientists to create complex cellular state machines and track cell histories.
07/21/16, ScienceDaily

Synthetic biology used to limit bacterial growth and coordinate drug release
Researchers have engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The strategy represents the use of synthetic biology in therapeutics.
07/20/16, ScienceDaily

Malaria: A genetically attenuated parasite induces an immune response
With nearly 3.2 billion people currently at risk of contracting malaria, scientists have experimentally developed a live, genetically attenuated vaccine for Plasmodium, the parasite responsible for the disease. By identifying and deleting one of the parasite's genes, the scientists enabled it to induce an effective, long-lasting immune response in a mouse model. These findings were published in the Journal of Experimental Medicine on July 18, 2016.
07/18/16, ScienceDaily

Gas sensors 'see' through soil to analyze microbial interactions
Researchers use programmed bacteria as gas sensors that help them 'see' into soil to learn about the behavior of the microbial communities within.
07/18/16, ScienceDaily

Proteins team up to turn on T cells
Scientists are learning how cells make the decision to become T cells.
07/15/16, ScienceDaily

Stem cells feel the force
Scientists have gained new insights into how stem cells feel and respond to external mechanical forces by changing the way DNA is organized in the nucleus, and thereby the expression of genes that are required for stem cell differentiation.
07/12/16, ScienceDaily

Researchers advance treatment possibilities for Gaucher, Parkinson's
Bethesda, Md., Mon., July 12, 2016 - NIH researchers have identified and tested a molecule that shows promise as a possible treatment for the rare Gaucher disease and the more common Parkinson's disease. These findings demonstrate how insights from a rare disorder can have direct relevance to the treatment of more common disorders. The findings were published July 12, 2016 in The Journal of Neuroscience.


07/12/16, National Human Genome Research Institute

<em>Media Availability</em>: Genetics of type 2 diabetes revealed in unprecedented detail
Bethesda, Md., Mon., July 11, 2016 - A comprehensive investigation of the underlying genetic architecture of type 2 diabetes has unveiled the most detailed look at the genetic differences that increase a person's risk for disease development. The findings, published July 11 in the journal Nature, reveal the complexity of the disease in more detail than previously appreciated and also identify several promising targets for new treatments.


07/11/16, National Human Genome Research Institute

Researchers harness DNA as the engine of super-efficient nanomachine
Researchers have established a way to harness DNA as the engine of a microscopic 'machine' they can turn on to detect trace amounts of substances that range from viruses and bacteria to cocaine and metals.
07/07/16, ScienceDaily

E. coli: The ideal transport vehicle for next-gen vaccines?
Researchers have developed an E. coli-based transport capsule designed to help next-generation vaccines do a more efficient and effective job than today's immunizations. The research highlights the capsule's success fighting pneumococcal disease, an infection that can result in pneumonia, sepsis, ear infections and meningitis.
07/01/16, ScienceDaily

Individual mycobacteria respond differently to antibiotics based on growth and timing
Scientists have identified factors that linked to why individual mycobacteria of the same genetic background can respond differently to antibiotics. The findings shed light on the complexity of antibiotic tolerance and may improve the future design of drug regimens.
07/01/16, ScienceDaily

Unsilencing silenced genes by CRISPR/Cas9
Scientists have developed a new technique to unleash silenced genes and change cell fates using CRISPR/Cas9.
07/01/16, ScienceDaily

Fix for 3-billion-year-old genetic error could dramatically improve genetic sequencing
Researchers found a fix for a 3-billion-year-old glitch in one of the major carriers of information needed for life, RNA, which until now produced errors when making copies of genetic information. The discovery will increase precision in genetic research and could dramatically improve medicine based on a person's genetic makeup.
06/23/16, ScienceDaily

A new bio-ink for 3-D printing with stem cells
Scientists have developed a new kind of bio-ink, which could eventually allow the production of complex tissues for surgical implants. The new stem cell-containing bio ink allows 3-D printing of living tissue, known as bio-printing.
06/23/16, ScienceDaily

Virus uses 'stolen' CRISPR to hack its host's immune system
Microbiologists have discovered that the Cyanophage N1 virus carries a DNA sequence -- a CRISPR -- that is generally used by bacteria to fight off viral infection. The virus appears to use the stolen bits of immune system DNA to highjack their hosts' immune response.
06/14/16, ScienceDaily

Gene-drive modified organisms are not ready to be released into environment, experts say
The emerging science of gene drives has the potential to address environmental and public health challenges, but gene-drive modified organisms are not ready to be released into the environment and require more research in laboratories and highly controlled field trials, says a new report.
06/08/16, ScienceDaily

Gene circuits in live cells can perform complex computations
Researchers have developed a technique to integrate both analogue and digital computation in living cells, allowing them to form gene circuits capable of carrying out complex processing operations.
06/03/16, ScienceDaily

Genetically modified golden rice falls short on lifesaving promises
Heralded on the cover of Time magazine in 2000 as a genetically modified (GMO) crop with the potential to save millions of lives in the Third World, Golden Rice is still years away from field introduction and even then, may fall short of lofty health benefits still cited regularly by GMO advocates, suggests a new study.
06/03/16, ScienceDaily

New CRISPR system for targeting RNA
Researchers have characterized a new CRISPR system that targets RNA, rather than DNA. The new approach has the potential to open a powerful avenue in cellular manipulation.
06/02/16, ScienceDaily

New 'genetic barcode' technique reveals details of cell lineage
By using the gene editing tool CRISPR to create unique genetic 'barcodes,' it's possible to track the lineage of cells in a living organism, a new study reveals.
05/26/16, ScienceDaily

Consumer knowledge gap on genetically modified food
While consumers are aware of genetically modified crops and food, their knowledge level is limited and often at odds with the facts, according to a newly published study.
05/25/16, ScienceDaily

New tools to manipulate biology
Chemistry has provided many key tools and techniques to the biological community in the last twenty years. We can now make proteins that Mother Nature never thought of, image unique parts of live cells and even see cells in live animals. Biologists now take these accomplishments a step further, reporting advances in both how proteins are made and how you can see their expression patterns in live animals.
05/24/16, ScienceDaily

A path away from reliance on oil, with the help of bacteria
Adding genes to bacteria offers sustainable routes to make compounds currently obtained from petrochemicals.
05/19/16, ScienceDaily

Biologists find how plants reconstitute stem cells
Stem cells are typically thought to have the intrinsic ability to generate or replace specialized cells. However, a team of biologists has shown that regenerating plants can naturally reconstitute their stem cells from more mature cells by replaying embryogenesis.
05/19/16, ScienceDaily

Genetically engineered crops: Experiences and prospects
An extensive study has found that new technologies in genetic engineering and conventional breeding are blurring the once clear distinctions between these two crop-improvement approaches.
05/17/16, ScienceDaily

Chance finding could transform plant production
An almost entirely accidental discovery by researchers could transform food and biofuel production and increase carbon capture on farmland. By tweaking a plant’s genetic profile, the researchers doubled the plant’s growth and increased seed production by more than 400 per cent.
05/17/16, ScienceDaily

NIH funds new studies on ethical, legal and social impact of genomic information
Bethesda, Md., Tues., May 17, 2016 - Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information. The awards will fund researchers at interdisciplinary centers through the National Human Genome Research Institute's (NHGRI) Centers of Excellence in Ethical, Legal and Social Implications Research (CEER) program.


05/17/16, National Human Genome Research Institute

Photosynthetic bacteria give biologists a cool new tool
Bioengineers have converted a protein pathway found in freshwater photosynthetic bacteria into the first engineered transcriptional regulatory tool that is activated exclusively by UV-violet light. The tool could make the manufacture of drugs and other substances by engineered bacteria more efficient.
05/10/16, ScienceDaily

NIH creates Atlas of Human Malformation Syndromes in Diverse Populations
Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, have collaborated with physicians and medical geneticists around the world to create the Atlas of Human Malformation Syndromes in Diverse Populations. Health care providers can use the new atlas to diagnose diverse patients with inherited diseases by comparing physical traits (called phenotypes) and written descriptions of their symptoms with photos and descriptions of people with the same condition and ancestry. Previously, the only available diagnostic atlas featured photos of patients with northern European ancestry, which often does not represent the characteristics of these diseases in patients from other parts of the world. The free electronic atlas was announced online in Genetics in Medicine.


04/29/16, National Human Genome Research Institute

Media Availability: NHGRI celebrates National DNA Day with events that promote genomic literacy
The National Human Genome Research Institute (NHGRI) will celebrate its fourteenth annual National DNA Day on Monday, April 25, 2016. National DNA Day commemorates the successful completion of the Human Genome Project in 2003 and the discovery of DNA's double helix in 1953. NHGRI, part of the National Institutes of Health (NIH), began celebrating this day annually on April 25, 2003, after the 108th Congress passed concurrent resolutions designating it as "National DNA Day." To mark this historic day, NHGRI is hosting events in the week leading up to and on National DNA Day.


04/11/16, National Human Genome Research Institute

'Honeycomb' of nanotubes could boost genetic engineering
Researchers have developed a new and highly efficient method for gene transfer. The technique, which involves culturing and transfecting cells with genetic material on an array of carbon nanotubes, appears to overcome the limitations of other gene editing technologies.
04/06/16, ScienceDaily

Pros and cons of mandatory GMO labeling
Researchers have concluded that mandatory labeling of genetically modified foods is justified, based on an extensive review of international scientific and legal frameworks related to genetically modified organisms (GMOs).
04/01/16, ScienceDaily

Proving the genetic code's flexibility
Three-letter codons in a genome sequence can represent one of the 20 regularly used amino acids or stops. Scientists have discovered that microorganisms recognize more than one codon for selenocysteine. The finding adds credence to recent studies indicating that an organism's genetic vocabulary is not as constrained as had been long held.
03/31/16, ScienceDaily

New tools allow rapid ID of CRISPR-Cas system PAMs
CRISPR-Cas systems are widely heralded as a new generation of genetic tools. But development of these tools requires researchers to identify the protospacer-adjacent motifs that unlock each system's functionality. A new set of techniques expedites PAM identification -- and early testing finds that many CRISPR-Cas systems actually have multiple PAMs of varying strength.
03/31/16, ScienceDaily

New methods of enhancing efficiency of genetic engineering in mice, rats
Two new gene modification methods have been developed: lsODN (long single-stranded oligodeoxynucleotide) and 2H2OP (two-hit two-oligo with plasmid). These methods use CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) -Cas systems and ssODN (single-stranded oligodeoxynucleotide).
03/24/16, ScienceDaily

For first time, scientists use CRISPR-Cas9 to target RNA in live cells
Scientists have long sought an efficient method for targeting RNA -- intermediary genetic material that carries the genetic code from the cell's nucleus to protein-making machinery -- in living cells. Researchers have now achieved this by applying the popular DNA-editing technique CRISPR-Cas9 to RNA.
03/17/16, ScienceDaily

NIH researchers identify striking genomic signature shared by five types of cancer
National Institutes of Health researchers have identified a signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer. The specific signature results from a chemical modification of DNA called methylation, which can control the expression of genes like a dimmer on a light switch. Researchers hope to spur development of a blood test that can be used to diagnose a variety of cancers at early stages. The study appears today, February 5, 2016, in The Journal of Molecular Diagnostics.


02/05/16, National Human Genome Research Institute

NIH Scientists Discover Genetic Cause of Rare Allergy to Vibration
Scientists at the National Institutes of Health (NIH) and the National Human Genome Research Institute have identified a genetic mutation responsible for a rare form of inherited hives induced by vibration, also known as vibratory urticaria. Running, hand clapping, towel drying or even taking a bumpy bus ride can cause temporary skin rashes in people with this rare disorder.


02/03/16, National Human Genome Research Institute

NIH genome sequencing program targets the genomic bases of common, rare disease
The National Institutes of Health will fund a set of genome sequencing and analysis centers whose research will focus on understanding the genomic bases of common and rare human diseases. The National Human Genome Research Institute (NHGRI), part of NIH, today launched the Centers for Common Disease Genomics (CCDG), which will use genome sequencing to explore the genomic contributions to common diseases such as heart disease, diabetes, stroke and autism. NHGRI also announced the next phase of a complementary program, the Centers for Mendelian Genomics (CMG), which will continue investigating the genomic underpinnings of rare, typically inherited diseases, such as cystic fibrosis and muscular dystrophy.


01/14/16, National Human Genome Research Institute

Individualized Medicine at Ocean Ridge Biosciences featured in The Palm Beach Post
Individualized Medicine at Ocean Ridge Biosciences featured in The Palm Beach Post...
06/17/15, ORB Company News

Identification of Circulating Biomarkers in Patients with Active Inflammatory Bowel Disease
ORB Contributes to New Findings in Inflammatory Bowel Disease Research Implications for the Development of a Non-Invasive Diagnostic Panel
Full Press Release...

03/09/15, ORB Company News

ORB Contributes to New Study Examining the RNA Content of Human Seminal Exosomes
Ocean Ridge Biosciences (ORB) is pleased to announce its contribution to a recent publication in volume 42 issue 11 of Nucleic Acids Research, entitled “Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions”. The article reveals potential mechanisms by which semen interferes with immune responses in the recipient fem...
07/23/14, ORB Company News

Ocean Ridge Contributes to Discovery of Biomarkers of Early-Stage Pancreatic Cancer
Ocean Ridge Biosciences is honored to announce its contribution to a landmark study to discover biomarkers of early-stage pancreatic cancer....
03/18/14, ORB Company News

ORB Contributes to Recently Published Study on Mechanisms of Aortic Valve Calcification
Ocean Ridge Biosciences (ORB) is honored to announce its contribution to a recently published, well respected publication titled, "Increased Dietary Intake of Vitamin A Promotes Aortic Valve Calcification In Vivo". ...
04/01/13, ORB Company News

Toxikon Forms Partnership with Ocean Ridge Biosciences
Preclinical CRO will globally market services and capabilities together with genomics services provider for development novel drugs and medical devices...
10/26/11, ORB Company News

ORB awarded grant for development of prognostic biomarkers of Emphysema
Ocean Ridge Biosciences, LLC (ORB) today announced that it has been awarded a $69,435 grant under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act....
11/02/10, ORB Company News

Contact Us

Ocean Ridge Biosciences, LLC
394 SW 12th Ave
Deerfield Beach, Florida 33442
Phone: 754-600-5128
Fax: 561-427-7845
Email: array@oceanridgebio.com